WO2013184985A1 - Inhibiteurs de la réplication de virus de la grippe - Google Patents

Inhibiteurs de la réplication de virus de la grippe Download PDF

Info

Publication number
WO2013184985A1
WO2013184985A1 PCT/US2013/044636 US2013044636W WO2013184985A1 WO 2013184985 A1 WO2013184985 A1 WO 2013184985A1 US 2013044636 W US2013044636 W US 2013044636W WO 2013184985 A1 WO2013184985 A1 WO 2013184985A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
optionally substituted
independently
compound
group
Prior art date
Application number
PCT/US2013/044636
Other languages
English (en)
Inventor
Paul S. Charifson
Mark W. Ledeboer
Michael P. Clark
Michael J. BOYD
Huai Gao
Brian Ledford
Francois Maltais
Emanuele Perola
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to EP13729577.0A priority Critical patent/EP2858984A1/fr
Publication of WO2013184985A1 publication Critical patent/WO2013184985A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Definitions

  • Influenza is primarily transmitted from person to person via large virus-laden droplets that are generated when infected persons cough or sneeze; these large droplets can then settle on the mucosal surfaces of the upper respiratory tracts of susceptible individuals who are near (e.g. within about 6 feet) infected persons. Transmission might also occur through direct contact or indirect contact with respiratory secretions, such as touching surfaces contaminated with influenza virus and then touching the eyes, nose or mouth.
  • respiratory secretions such as touching surfaces contaminated with influenza virus and then touching the eyes, nose or mouth.
  • Adults might be able to spread influenza to others from 1 day before getting symptoms to approximately 5 days after symptoms start. Young children and persons with weakened immune systems might be infectious for 10 or more days after onset of symptoms.
  • Influenza viruses are RNA viruses of the family Orthomyxoviridae, which comprises five genera: Influenza virus A, Influenza virus B, Influenza virus C, Isavirus and Thogoto virus.
  • influenza A virus has one species, influenza A virus. Wild aquatic birds are the natural hosts for a large variety of influenza A. Occasionally, viruses are transmitted to other species and may then cause devastating outbreaks in domestic poultry or give rise to human influenza pandemics.
  • the type A viruses are the most virulent human pathogens among the three influenza types and cause the most severe disease.
  • the influenza A virus can be subdivided into different serotypes based on the antibody response to these viruses.
  • Hl l which caused Spanish influenza in 1918
  • H2N2 which caused Asian Influenza in 1957
  • H3N2 which caused Hong Kong Flu in 1968
  • H5N1 a pandemic threat in the 2007-08 influenza season
  • H7N7 which has unusual zoonotic potential
  • H1N2 endemic in humans and pigs
  • H9N2, H7N2 , H7N3 and H10N7 are: Hl l (which caused Spanish influenza in 1918), H2N2 (which caused Asian Influenza in 1957), H3N2 (which caused Hong Kong Flu in 1968), H5N1 (a pandemic threat in the 2007-08 influenza season), H7N7 (which has unusual zoonotic potential), H1N2 (endemic in humans and pigs), H9N2, H7N2 , H7N3 and H10N7.
  • influenza B virus The Influenza virus B genus has one species, influenza B virus. Influenza B almost exclusively infects humans and is less common than influenza A. The only other animal known to be susceptible to influenza B infection is the seal. This type of influenza mutates at a rate 2-3 times slower than type A and consequently is less genetically diverse, with only one influenza B serotype. As a result of this lack of antigenic diversity, a degree of immunity to influenza B is usually acquired at an early age. However, influenza B mutates enough that lasting immunity is not possible. This reduced rate of antigenic change, combined with its limited host range (inhibiting cross species antigenic shift), ensures that pandemics of influenza B do not occur.
  • influenza C The Influenza virus C genus has one species, influenza C virus, which infects humans and pigs and can cause severe illness and local epidemics. However, influenza C is less common than the other types and usually seems to cause mild disease in children.
  • Influenza A, B and C viruses are very similar in structure.
  • the virus particle is 80-120 nanometers in diameter and usually roughly spherical, although filamentous forms can occur.
  • Unusually for a virus, its genome is not a single piece of nucleic acid; instead, it contains seven or eight pieces of segmented negative-sense RNA.
  • the Influenza A genome encodes 1 1 proteins: hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), Ml, M2, NS1, NS2( EP), PA, PB1, PB1-F2 and PB2.
  • HA and NA are large glycoproteins on the outside of the viral particles.
  • HA is a lectin that mediates binding of the virus to target cells and entry of the viral genome into the target cell, while NA is involved in the release of progeny virus from infected cells, by cleaving sugars that bind the mature viral particles.
  • these proteins have been targets for antiviral drugs.
  • they are antigens to which antibodies can be raised.
  • Influenza A viruses are classified into subtypes based on antibody responses to HA and NA, forming the basis of the H and N distinctions (vide supra) in, for example, H5N1.
  • Influenza produces direct costs due to lost productivity and associated medical treatment, as well as indirect costs of preventative measures. In the United States, influenza is responsible for a total cost of over $ 10 billion per year, while it has been estimated that a future pandemic could cause hundreds of billions of dollars in direct and indirect costs.
  • influenza vaccine Current treatment options for influenza include vaccination, and chemotherapy or chemoprophylaxis with anti-viral medications.
  • Vaccination against influenza with an influenza vaccine is often recommended for high-risk groups, such as children and the elderly, or in people that have asthma, diabetes, or heart disease.
  • the vaccine is reformulated each season for a few specific influenza strains but cannot possibly include all the strains actively infecting people in the world for that season. It takes about six months for the manufacturers to formulate and produce the millions of doses required to deal with the seasonal epidemics; occasionally, a new or overlooked strain becomes prominent during that time and infects people although they have been vaccinated (as by the H3N2 Fujian flu in the 2003-2004 influenza season). It is also possible to get infected just before vaccination and get sick with the very strain that the vaccine is supposed to prevent, as the vaccine takes about two weeks to become effective.
  • influenza vaccines are variable. Due to the high mutation rate of the virus, a particular influenza vaccine usually confers protection for no more than a few years. A vaccine formulated for one year may be ineffective in the following year, since the influenza virus changes rapidly over time, and different strains become dominant.
  • RNA-dependent RNA polymerase of influenza vRNA makes a single nucleotide insertion error roughly every 10 thousand nucleotides, which is the approximate length of the influenza vRNA.
  • nearly every newly-manufactured influenza virus is a mutant— antigenic drift.
  • the separation of the genome into eight separate segments of vRNA allows mixing or reassortment of vRNAs if more than one viral line has infected a single cell.
  • the resulting rapid change in viral genetics produces antigenic shifts and allows the virus to infect new host species and quickly overcome protective immunity.
  • Antiviral drugs can also be used to treat influenza, with neuraminidase inhibitors being particularly effective, but viruses can develop resistance to the standard antiviral drugs.
  • the present invention generally relates to methods of treating influenza, to methods of inhibiting the replication of influenza viruses, to methods of reducing the amount of influenza viruses, and to compounds and compositions that can be employed for such methods.
  • the present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof:
  • X 1 is -CI, -CN, -CF 3 , or -CH 3 ;
  • X 2 is -H, -F, or -CI
  • Ring T is a C3-C1 0 carbocyclic group optionally further substituted with one or more
  • Z 1 and Z 2 are each independently CH or N;
  • Q 1 is -C(O)-, -C(0)0-, -OC(O)-, -0-, -C(0)NR'-, NRC(O)-, -NRC(0)NR'-, -OC(0)NR'-,-S(0)-, -S(0) 2 -, -S0 2 NR'-, -NRS0 2 - -NRS0 2 NR'-, -P(0)(OR)0-,
  • optionally -Q x -R 2 forms, together with the carbon atom of Ring T to which -Q x -R 2 is attached, forms a 4-10 membered (or 5-7 membered), non-aromatic, spiro ring optionally substituted with one or more instances of J R ;
  • Q 2 is -CH 2 -[C(R 7 R 8 )] n -;
  • R 2 is -H, a C1-C6 aliphatic group optionally substituted with one or more J A , a C3-C8 carbocyclic group optionally substituted with one or more J B , or a 4-10 membered heterocyclic group optionally substituted with one or more J c , or optionally R 2 , together with R' and the nitrogen atom of Q 1 to which they are attached (that is NR'R 2 of Q l R 2 when Q 1 is -C(0)NR'-, NRC(O)-, -NRC(0)NR'-, -OC(0)NR'-, -SO2NR'-, -NRSO2-, or-NRS0 2 NR'-), forms a 4-8 membered heterocyclic group optionally substituted with one or more instances of J R ; or
  • R 2 is a C1-C6 aliphatic group substituted with one or more M, a 5-7 membered heterocyclic group optionally substituted with one or more J 2 , or a 5-6 membered heteroaryl group optionally substituted with one or more J 3 ;
  • R 3 is -C(0)OR, -S(0)R 9 , -S(0) 2 R 9 , -S(0) 2 NRR 10 , -OR, P(0)(OR) 2 , or CH 2 OR;
  • R 4 , R 5 , and R 6 are each and independently -CH 3 , -CH 2 F, -CF 3 , -C 2 H 5 , -CH 2 CH 2 F, or -CH 2 CF 3 ; or optionally R 5 and R 6 , or R 4 , R 5 and R 6 , together with the carbon atom to which they are attached, form a C3-C1 0 carbocyclic ring;
  • R 7 and R 8 are each and independently -H, -OH, -CH 3 , or -CF 3 ; or optionally, R 7 and R 8 together with the carbon atoms to which they are attached form a cyclopropane ring; each R 9 is independently -OR or C1-C6 alkyl optionally substituted with one or more instances of J 1 ;
  • R 10 is -H or C1-C6 alkyl optionally substituted with one or more instances of J 1 ;
  • R and R' are each independently -H or C1-C6 alkyl optionally substituted with one or more instances of J 1 , or optionally R and R', together with the nitrogen to which they are attached, form a 4-8 membered heterocyclic group optionally substituted with one or more instances of J R ;
  • J T is selected from the group consisting of halogen, cyano, oxo, hydroxy, -NH 2 , -NH(Ci-C 4 alkyl), -N(Ci-C 4 alkyl) 2 , -OCO(Ci-C 4 alkyl), -CO(Ci-C 4 alkyl), -C0 2 H, -C0 2 (Ci- C 4 alkyl), Ci-C 4 alkyl, Ci-C 4 haloalkyl, C 3 -C 6 cycloalkyl, and -0(Ci-C 4 alkyl);
  • J A is halogen, cyano, oxo, R d , or M;
  • J B and J c are each and independently selected from the group consisting of halogen, cyano, oxo, M, -R a , and -R a -M; or
  • R a is independently:
  • Ci-Ce aliphatic group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH 2 , -NH(Ci-C 4 alkyl), -N(C 1 -C 4 alkyl) 2 , -OCO(Ci-C 4 alkyl), -CO(Ci-C 4 alkyl), -C0 2 H, -C0 2 (Ci-C 4 alkyl), -0(Ci-C 4 alkyl), C3-C8 carbocyclic group optionally substituted with one or more instances of J 2 , 4-8 membered heterocyclic group optionally substituted with one or more instances of J 2 , 5-6 membered heteroaryl group optionally substituted with one or more instances of J 3 , and phenyl optionally substituted with one or more instances of J 3 ;
  • R b and R c are each independently R a or -H; or optionally, R b and R c , together with the nitrogen atom(s) to which they are attached, each independently form a 4-8 membered heterocyclic group optionally substituted with one or more instances of J R ;
  • R d is C3-C8 carbocyclic group optionally substituted with one or more instances of J 2 , 4-8 membered heterocyclic group optionally substituted with one or more instances of J 2 , 5-6 membered heteroaryl group optionally substituted with one or more instances of J 3 , or phenyl optionally substituted with one or more instances of J 3 ;
  • each J 1 is independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH 2 , -NH(Ci-C 4 alkyl), -N(Ci-C 4 alkyl) 2 , -OCO(Ci-C 4 alkyl), -CO(Ci-C 4 alkyl), -C0 2 H, -C0 2 (Ci-C 4 alkyl), -0(Ci-C 4 alkyl), and phenyl;
  • each J 2 is independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH 2 , -NH(Ci-C 4 alkyl), -N(Ci-C 4 alkyl) 2 , -OCO(Ci-C 4 alkyl), -CO(Ci-C 4 alkyl), -C0 2 H, -C0 2 (Ci-C 4 alkyl), Ci-C 4 alkyl, Ci-C 4 haloalkyl, and -0(Ci-C 4 alkyl);
  • each of J 3 and J R is independently selected from the group consisting of halogen, cyano, hydroxy, -NH 2 , -NH(Ci-C 4 alkyl), -N(Ci-C 4 alkyl) 2 , -OCO(Ci-C 4 alkyl), -CO(Ci-C 4 alkyl), -C0 2 H, -C0 2 (Ci-C 4 alkyl), Ci-C 4 alkyl, Ci-C 4 haloalkyl, and -0(Ci-C 4 alkyl); and n is independently 0 or 1.
  • the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound disclosed herein (e.g., a compound represented by any one of Structural Formulae (I) - (V), or a pharmaceutically acceptable salt thereof) and a pharmaceutically acceptable carrier, adjuvant or vehicle.
  • the present invention is directed to a method of inhibiting the replication of influenza viruses in a biological sample or patient, comprising the step of administering to said biological sample or patient an effective amount of a compound disclosed herein (e.g., a compound represented by any one of Structural Formulae (I) - (V), or a pharmaceutically acceptable salt thereof).
  • a compound disclosed herein e.g., a compound represented by any one of Structural Formulae (I) - (V), or a pharmaceutically acceptable salt thereof.
  • the present invention is directed to a method of reducing the amount of influenza viruses in a biological sample or in a patient, comprising administering to said biological sample or patient an effective amount of a compound disclosed herein (e.g., a compound represented by any one of Structural Formulae (I) - (V), or a pharmaceutically acceptable salt thereof).
  • a compound disclosed herein e.g., a compound represented by any one of Structural Formulae (I) - (V), or a pharmaceutically acceptable salt thereof.
  • the present invention is directed to a method of method of treating influenza in a patient, comprising administering to said patient an effective amount of a compound disclosed herein (e.g., a compound represented by any one of Structural Formulae (I) - (V), or a pharmaceutically acceptable salt thereof).
  • a compound disclosed herein e.g., a compound represented by any one of Structural Formulae (I) - (V), or a pharmaceutically acceptable salt thereof.
  • the present invention also provides use of the compounds described herein for inhibiting the replication of influenza viruses in a biological sample or patient, for reducing the amount of influenza viruses in a biological sample or patient, or for treating influenza in a patient.
  • Also provided herein is use of the compounds described herein for the manufacture of a medicament for treating influenza in a patient, for reducing the amount of influenza viruses in a biological sample or in a patient, or for inhibiting the replication of influenza viruses in a biological sample or patient.
  • the compounds of Structural Formula (XX) can be used for synthesizing the compounds of Formula (I).
  • the variables of Structural Formula (XX) are each and independently as defined herein; and G is trityl (-C(Ph) 3 ).
  • the invention also provides methods of preparing a compound represented by
  • Structural Formula (I) or a pharmaceutically acceptable salt thereof employ the steps of:
  • L 2 is a halogen
  • G is trityl
  • the compounds of the invention are as described in the claims.
  • the compounds of the invention are represented by any one of Structural Formulae (I) - (V), or pharmaceutically acceptable salts thereof, wherein the variables are each and independently as described in any one of the claims.
  • the compounds of the invention are represented by any chemical formulae depicted in Table 1, or pharmaceutically acceptable salts thereof.
  • the compounds of the invention are presented by Structural Formulae (I) - (V), or a pharmaceutically acceptable salt thereof, wherein the variables are each and independently as depicted in the chemical formulae in Table 1.
  • the compounds of the invention are represented by Structural Formula (I) or pharmaceutically acceptable salts thereof:
  • X 1 is -CI, -CN, -CF 3 , or -CH 3 . In one aspect, X 1 is -CI, or -CF 3 . In another aspect, X 1 is -CI.
  • X 2 is -H, -F, or -CI. In one aspect, X is -F or -CI. In another aspect, X is -F.
  • Ring T is a C3-C 10 carbocyclic group optionally further substituted with one or more J T .
  • Ring T can be a mono-cyclic, bi-cyclic, polycyclic, bridged, non-bridged, or fused ring system.
  • Ring T is an optionally substituted C5-C 10 carbocyclic ring.
  • Ring T is an optionally substituted C5-C6 mono-cyclic group.
  • Ring T is an optionally substituted C7-C 10 bridged carbocyclic ring.
  • a typical example of (Ring T)-Q -R Ring A is a C5-C7 monocyclic group or C7-C 10 bridged carbocyclic group, each of which independently and optionally further substituted with one or more instances of J T ; or optionally Ring A and R 13 , Ring A and R 14 , or Ring A and R 15 , form a C7-C 10 bridged carbocyclic ring optionally further substituted with one or more instances of J T .
  • Certain more typical examples of (Ring T)-Q 1 - R 2 include:
  • rings A1-A4 is independently a C7-C1 0 bridged, carbocyclic ring optionally further substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, C1-C4 alkyl, C 1 -C 4 haloalkyl, and -0(Ci-C 4 alkyl); and each of rings A5-A6 is independently and optionally further substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C3-C5 cycloalkyl, and -0(Ci-C 4 alkyl).
  • Z 1 and Z 2 are each independently CH or N. In one aspect, Z 1 and Z 2 are each independently CH.
  • Each Q 1 is independently -C(O)-, -C(0)0-, -OC(O)-, -0-, -C(0)NR'-, NRC(O)-, -NRC(0)NR'-, -OC(0)NR'-,-S(0)-, -S(0) 2 -, -S0 2 NR'-, -NRS0 2 - -NRS0 2 NR'-,
  • Q 1 is -C(0)0-, -NRC(O)-, -C(0)NR'-, or -NRC(0)NR'-.
  • each Q 1 is independently -C(0)0-, -NHC(O)-, or -NHC(0)NR'-.
  • each Q 1 is independently -C(0)0-.
  • each Q 1 is independently -NHC(O)- or -NHC(0)NR'-.
  • -Q x -R 2 forms, together with the carbon atom of Ring T to which -Q x -R 2 is attached, forms a 4-10 membered, non-aromatic, spiro ring optionally substituted with one or more instances of J R .
  • the spiro ring formed with -Q x -R 2 is an optionally substituted, 5-7 membered ring.
  • Q 2 is -CH 2 -[C(R 7 R 8 )]n-. In one aspect, -CH 2 -[CH 2 ] n -. In another aspect, Q 2 is -CH 2 .
  • R 2 is -H, a C1-C6 aliphatic group optionally substituted with one or more J A , a C3-C8 carbocyclic group optionally substituted with one or more J B , or a 4-10 membered heterocyclic group optionally substituted with one or more J c , or optionally, R 2 , together with R' and the nitrogen atom of Q 1 to which they are attached (that is NR'R 2 of Q X R 2 when Q 1 is -C(0)NR'-, NRC(O)-, -NRC(0)NR'-, -OC(0)NR'-, -S0 2 NR'-, -NRSO 2 -, or-NRS0 2 NR'-), form a 4-8 membered heterocyclic group optionally substituted with one or more instances of J R .
  • R 2 is a C 1 -C6 aliphatic group substituted with one or more M, a 5-7 membered heterocyclic group optionally substituted with one or more J 2 , or a 5-6 membered heteroaryl group optionally substituted with one or more J 3 .
  • Q 1 is other than a bond; and R 2 is independently -H, an optionally substituted C 1 -C6 alkyl, an optionally substituted 5-7 membered heterocyclic group, an optionally substituted phenyl group, or an optionally substituted 5-6 membered heteroaryl group; or optionally R 2 and R', together with the nitrogen atom to which they are attached, form an optionally substituted, 5-7 membered heterocyclic group; wherein said C 1 -C6 alkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, and -0(Ci-C 4 alkyl); and each of said heterocyclic, phenyl and heteroaryl groups is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, Ci-C 4 alkyl, Ci-C 4 haloalkyl, and -0(Ci-C 4 alkyl
  • Q 1 is other than a bond; and R 2 is - H, optionally substituted Ci_6 alkyl, optionally substituted 5-6 membered heterocyclic, or optionally substituted 5-6 membered heteroaryl.
  • Q 1 is other than a bond; and R 2 is -H, optionally substituted Ci_6 alkyl, or optionally substituted 5-6 membered heterocyclic.
  • Q 1 is other than a bond; and R 2 is -H or optionally substituted Ci_6 alkyl.
  • R 2 when Q 1 is a bond, R 2 is a C 1 -C6 alkyl group substituted with one or more M; an optionally substituted, 5-7 membered, heterocyclic group; or an optionally substituted, 5-6 membered heteroaryl group. In yet another aspect, when Q 1 is a bond, R 2 is a C1-C6 alkyl group substituted with one or more M.
  • R 3 is -C(0)OR, -S(0)R 9 , -S(0) 2 R 9 , -S(0) 2 NRR 10 , -OR, P(0)(OR) 2 , or CH 2 OR.
  • R 3 is -C(0)OR, -OH, -CH 2 OH, -S(0) 2 R 9 , or -S(0) 2 -NRR 10 .
  • R 3 is -C(0)OR, -S(0) 2 R 9 , or -S(0) 2 -NRR 10 .
  • R 3 is -C(0)OR.
  • R 4 , R 5 , and R 6 are each and independently -CH 3 , -CH 2 F, -CF 3 , -C 2 H 5 , -CH 2 CH 2 F, or -CH 2 CF 3 ; or optionally R 5 and R 6 , or R 4 , R 5 and R 6 , together with the carbon atom to which they are attached, form a 3-10 membered carbocyclic ring.
  • R 4 , R 5 , and R 6 are each and independently -CH 3 , -CH 2 F, -CF 3 , or -C 2 H 5 ; or R 4 is -CH 3 , -CH 2 F, -CF 3 , or -C 2 H 5 ; and R 5 and R 6 together with the carbon atom to which they are attached form a C 3 -C6 carbocyclic ring.
  • R 4 , R 5 , and R 6 are each and independently -CH 3 or - C2H5.
  • R 4 is -CH 3 or -C2H5; and R 5 and R 6 together with the carbon atom to which they are attached form a C3-C6 carbocyclic ring.
  • R 7 and R 8 are each and independently -H, -OH, -CH 3 , or -CF 3 ; or optionally, R 7 and R 8 together with the carbon atoms to which they are attached form a cyclopropane ring.
  • R 7 and R 8 are each and independently -H, -OH, -CH 3 , or -CF 3 .
  • R 7 and R 8 are each and independently -H or -CH 3 .
  • R 7 and R 8 are each and independently -H.
  • Each R 9 is independently -OR or C -Ce alkyl optionally substituted with one or more instances of J 1 . In one aspect, each R 9 is -OH.
  • R 10 is -H or Ci-Ce alkyl optionally substituted with one or more instances of J 1 .
  • R 10 is C 1-4 alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, -OR and -C(0)OR.
  • R and R' are each independently -H or Ci-Ce alkyl optionally substituted with one or more instances of J 1 , or optionally R and R', together with the nitrogen to which they are attached, form a 4-8 membered heterocyclic group optionally substituted with one or more instances of J R .
  • J T is selected from the group consisting of halogen, cyano, oxo, hydroxy, -NH 2 , -NH(Ci-C 4 alkyl), -N(Ci-C 4 alkyl) 2 , -OCO(Ci-C 4 alkyl), -CO(Ci-C 4 alkyl), -C0 2 H, -C0 2 (Ci- C 4 alkyl), Ci-C 4 alkyl, Ci-C 4 haloalkyl, C 3 -C 6 cycloalkyl, and -0(Ci-C 4 alkyl).
  • J A is halogen, cyano, oxo, R d , or M.
  • J B and J c are each and independently selected from the group consisting of halogen, cyano, oxo, M, -R a , and -R a -M.
  • two J T , two J A , two J B , and two J c together with the atom(s) to which they are attached, independently form a 4-8-membered ring that is optionally substituted with one or more instances of J R .
  • each M is independently selected from the group consisting of -OR b , -SR b , -S(0)R a , -S0 2 R a , -NR b R c , -C(0)R a , -C(0)OR b , -OC(0)R b , -NRC(0)R b , -C(0)NR b R c ,
  • each M is independently selected from the group consisting of -OR b , -NR b R c , -C(0)R a , -C(0)OR b , -OC(0)R b , -NRC(0)R b , -C(0)NR b R c , -NRC(0)NR b R c , -NRC(0)OR b , -OCONR b R c , -S0 2 NR c R b , -NRS0 2 R b , and -NRS0 2 NR b R c .
  • each M is independently selected from the group consisting of -OR b , -NHR C , -C(0)R a , -C(0)OR b , -OC(0)R b , -NHC(0)R b , -C(0)NHR c , -C(0)NR b R c , -NHC(0)NHR c , -NHC(0)OR b , -OCONHR c , -S0 2 NHR b , -NHS0 2 R b , and -NHS0 2 NHR c , wheren R b and R c of -C(0)NR b R c , form a 5-6 membered heterocyclic group.
  • each M is independently selected from the group consisting of -OH, -0(Ci-C 6 alkyl), -NH(Ci-C 6 alkyl), -C(0)(Ci-C 6 alkyl), -C(0)OH, -C(0)0(Ci-C 6 alkyl), -OC(0)(Ci-C 6 alkyl), -NHC(0)(Ci-C 6 alkyl), -NHC(0)(5- 6 membered heteroaryl), -NHC(0)(5-6 membered heterocyclic group), -C(0)NH(Ci-C6 alkyl), -NHC(0)NH(Ci-C 6 alkyl), -NHC(0)0(Ci-C 6 alkyl), -OCONH(Ci-C 6 alkyl), -S0 2 NH(Ci-C 6 alkyl), -NHS0 2 (Ci-C 6 alkyl), and -NHS0 2 NH(Ci-C 6 alkyl)
  • each M is independently selected from the group consisting of -OH, -0(Ci-C6 alkyl), -NH(Ci-C 6 alkyl), -C(0)OH, -C(0)0(Ci-C 6 alkyl), -OC(0)(Ci-C 6 alkyl), -NHC(0)(Ci-C 6 alkyl), -NHC(0)(5-6 membered heterocyclic group), -C(0)NH(Ci-C 6 alkyl), -S0 2 NH(Ci- C 6 alkyl), and -NHS0 2 (Ci-C 6 alkyl).
  • Each R a is independently: i) a C 1 -C6 aliphatic group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH 2 , -NH(Ci-C 4 alkyl), -N(Ci-C 4 alkyl) 2 , -OCO(Ci-C 4 alkyl), -CO(Ci-C 4 alkyl), -C0 2 H, -C0 2 (Ci- C 4 alkyl), -0(Ci-C 4 alkyl), C3-C8 carbocyclic group optionally substituted with one or more instances of J 2 , 4-8 membered heterocyclic group optionally substituted with one or more instances of J 2 , 5-6 membered heteroaryl group optionally substituted with one or more instances of J 3 , and phenyl optionally substituted with one or more instances of J 3 ; ii) a C3-C8
  • each R a is independently an optionally substituted C 1 -C6 alkyl group, an optionally substituted C3-C7 carbocyclic group, an optionally substituted 5-7 membered heterocyclic group, an optionally substituted 5-6 membered heteroaryl group, or an optionally substituted phenyl group.
  • R b and R c are each independently R a or -H; or optionally, R b and R c , together with the nitrogen atom(s) to which they are attached, each independently form a 4-8 membered heterocyclic group optionally substituted with one or more instances of J R .
  • R b and R c are each independently R a or -H; or optionally, R b and R c , together with the nitrogen atom(s) to which they are attached, each independently form an optionally substituted 5-7 membered heterocyclic group.
  • R d is C3-C8 carbocyclic group optionally substituted with one or more instances of J 2 , 4-8 membered heterocyclic group optionally substituted with one or more instances of J 2 , 5-6 membered heteroaryl group optionally substituted with one or more instances of J 3 , or phenyl optionally substituted with one or more instances of J 3 .
  • R d is independently an optionally substituted C3-C6 carbocyclic group, an optionally substituted 5-7 membered heterocyclic group.
  • J A is halogen, cyano, oxo, an optionally substituted C3-C6 carbocyclic group, an optionally substituted 5-7 membered heterocyclic group, or M. In another aspect, J A is halogen, cyano, oxo, or M.
  • J A is halogen, cyano, oxo, -OH, - 0(Ci-C 6 alkyl), -NH(Ci-C 6 alkyl), -C(0)OH, -C(0)0(Ci-C 6 alkyl), -OC(0)(Ci-C 6 alkyl), -NHC(0)(Ci-C 6 alkyl), -NHC(0)(5-6 membered heterocyclic group), -C(0)NH(Ci-C 6 alkyl), -S0 2 NH(Ci-C 6 alkyl), or -NHS0 2 (Ci-C 6 alkyl).
  • J B and J c are each and independently is halogen, cyano, oxo, M, an optionally substituted C1-C6 alkyl group, an optionally substituted C3-C6 carbocyclic group, an optionally substituted 5-7 membered heterocyclic group, an optionally substituted 5-7 membered heteroaryl group, or an optionally substituted phenyl group.
  • J B and J c are each and independently is halogen; cyano; oxo; -OH; -0(Ci-C6 alkyl); - H(Ci-C6 alkyl); -C(0)OH; -C(0)0(Ci-C 6 alkyl); -OC(0)(Ci-C 6 alkyl); -NHC(0)(Ci-C 6 alkyl); -NHC(0)(5-6 membered heterocyclic group); -C(0)NH(Ci-C 6 alkyl); -S0 2 NH(Ci-C 6 alkyl),; - HS0 2 (Ci-C6 alkyl); or a C1-C6 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH 2 , -NH(Ci-C 4 alkyl), -N(Ci-C 4 alkyl) 2 ,
  • Each J 1 is independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH 2 , -NH(Ci-C 4 alkyl), -N(Ci-C 4 alkyl) 2 , -OCO(Ci-C 4 alkyl), -CO(Ci-C 4 alkyl), -C0 2 H, -C0 2 (Ci-C 4 alkyl), -0(Ci-C 4 alkyl), and phenyl.
  • Each J 2 is independently selected from the group consisting of halogen, cyano, hydroxy, oxo, -NH 2 , -NH(Ci-C 4 alkyl), -N(Ci-C 4 alkyl) 2 , -OCO(Ci-C 4 alkyl), -CO(Ci-C 4 alkyl), -C0 2 H, -C0 2 (Ci-C 4 alkyl), Ci-C 4 alkyl, Ci-C 4 haloalkyl, and -0(Ci-C 4 alkyl).
  • Each of J 3 and J R is independently selected from the group consisting of halogen, cyano, hydroxy, -NH 2 , -NH(Ci-C 4 alkyl), -N(Ci-C 4 alkyl) 2 , -OCO(Ci-C 4 alkyl), -CO(Ci-C 4 alkyl), -C0 2 H, -C0 2 (Ci-C 4 alkyl), Ci-C 4 alkyl, d-C 4 haloalkyl, and -0(Ci-C 4 alkyl).
  • n is independently 0 or 1.
  • x is 0, 1 or 2. In one aspect, x is 0 or 1.
  • Each p is independently 1, 2, or 3. In one aspect, each p is independently 2 or 3.
  • Each q is independently 0, 1 or 2. In one aspect, each q is independently 0 or 1.
  • Each r is independently 1 or 2.
  • X 1 is -CI, or -CF 3 .
  • X 2 is -F or -CI.
  • X 1 and X 2 are each independently as described above in the first or second set of set of values of the variables of Structural Formula (I).
  • M is independently selected from the group consisting of -OR b , -SR b , -S(0)R a ,
  • X 1 and X 2 are each independently as described above in the first or second set of set of values of the variables of Structural Formula (I).
  • M is each independently as described above in the first or third set of set of values of the variables of Structural Formula (I).
  • J T is selected from the group consisting of halogen, cyano, hydroxy, -NH 2 , -NH(Ci-C 4 alkyl), -N(Ci-C 4 alkyl) 2 , -OCO(Ci-C 4 alkyl), -CO(Ci-C 4 alkyl), -C0 2 H, -C0 2 (Ci-C 4 alkyl), Ci-C 4 alkyl, d-C 4 haloalkyl, C 3 -C 6 cycloalkyl, and -0(Ci-C 4 alkyl).
  • J A is halogen, cyano, oxo, R d , -OR b , -NHR C , -C(0)R b , -C(0)OR b , -OC(0)R b , -NHC(0)R b , -C(0)NHR c , -NHC(0)NHR c , -NHC(0)OR b , -OCONHR c , -N(CH 3 )R C , -N(CH 3 )C(0)R b , -C(0)N(CH 3 )R c , -N(CH 3 )C(0)NHR c , -N(CH 3 )C(0)OR b , -NHS0 2 R b , -S0 2 NHR b , -S0 2 N(CH 3 )R b , and -N(CH 3 )S0 2 R b .
  • J and J are each and independently selected from the group consisting of halogen, cyano, oxo, R a , -OR b , -NHR C , -C(0)R b , -C(0)OR b , -OC(0)R b , -NHC(0)R b , -C(0)NHR c , -NHC(0)NHR c , -NHC(0)OR b , -OCONHR c , -N(CH 3 )R C , -N(CH 3 )C(0)R b ,
  • X 1 and X 2 are each independently as described above in the first or second set of set of values of the variables of Structural Formula (I).
  • M is each independently as described above in the first or third set of set of values of the variables of Structural Formula (I).
  • J T , J A , J B , and J c is independently as described above in the first or fourth set of set of values of the variables of Structural Formula (I).
  • R a is independently an optionally substituted C1-C6 alkyl group, an optionally substituted C3-C7 carbocyclic group, an optionally substituted 5-7 membered heterocyclic group, an optionally substituted 5-6 membered heteroaryl group, or an optionally substituted phenyl group;
  • R b and R c are each independently R a or -H; or optionally, R b and R c , together with the nitrogen atom(s) to which they are attached, each independently form an optionally substituted 5-7 membered heterocyclic group.
  • R d is independently an optionally substituted C 3 -C6 carbocyclic group or an optionally substituted 5-7 membered heterocyclic group.
  • the compounds of the invention are represented by any one of Structural Formula (II) or pharmaceutically acceptable salts thereof:
  • values of the variables of Structural Formula (II) are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Q 1 is -C(0)0-, -NRC(O)-, -C(0)NR'-, or -NRC(0)NR'-.
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Ring T is an optionally substituted C5-C1 0 carbocyclic ring. In one aspect, Ring T is an optionally substituted C5-C6 mono-cyclic group. In another aspect, Ring T is an optionally substituted C7-C1 0 bridged carbocyclic ring.
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Q 1 is as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I) or in the sixth set of values of the variables of Structural Formula (II).
  • Ring T-Q ⁇ R 2 is:
  • Ring A is a C5-C7 monocyclic group or C7-C1 0 bridged carbocyclic group, each of which independently and optionally further substituted with one or more instances of J T ; or optionally Ring A and R 13 , Ring A and R 14 , or Ring A and R 15 , independently form a C7-C1 0 bridged carbocyclic ring optionally further substituted with one or more instances of J T ;
  • R 12 , R 13 , and R 14 are each independently -H, -F, hydroxy, -NH 2 , -NH(Ci-C 4 alkyl), -N(Ci-C 4 alkyl) 2 , -OCO(Ci-C 4 alkyl), -CO(Ci-C 4 alkyl), -C0 2 H, -C0 2 (Ci-C 4 alkyl), Ci-C 4 alkyl, Ci-C 4 haloalkyl, or -0(Ci-C 4 alkyl);
  • R 15 is -H, -F, hydroxy, Ci-C 4 alkyl, or Ci-C 4 haloalkyl
  • x 0, 1 or 2.
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Ring A and x are each independently as described above in the eighth set of values of the variables of Structural Formula (II).
  • R 12 is -H, hydroxy, d-C 4 alkyl, Ci-C 4 haloalkyl, or -0(Ci-C 4 alkyl).
  • R 13 is -H, hydroxy, Ci-C 4 alkyl, Ci-C 4 haloalkyl, or -0(Ci-C 4 alkyl), or optionally, together with Ring A, forms an optionally substituted C7-C1 0 bridged, carbocyclic ring.
  • R 14 is -H, Ci-C 4 alkyl, or Ci-C 4 haloalkyl; or optionally, together with Ring A, forms an optionally substituted C7-C1 0 bridged, carbocyclic ring.
  • R 15 is -H, C 1 -C 4 alkyl, or Ci-C 4 haloalkyl; or optionally, together with Ring A, forms an optionally substituted, C7-C1 0 bridged, carbocyclic ring.
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Q 1 is as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I) or in the sixth set of values of the variables of Structural Formula (II).
  • Ring A and x are each independently as described above in the eighth set of values of the variables of Structural Formula (II).
  • R is -H.
  • R is -H or optionally, together with Ring A, forms an optionally substituted C7-C1 0 bridged, carbocyclic ring.
  • R is -H or optionally, together with Ring A, forms an optionally substituted, C7-C1 0 bridged, carbocyclic ring.
  • R 15 is -H or C1-C4 alkyl, or optionally, together with Ring A, forms an optionally substituted C7-C1 0 bridged, carbocyclic ring.
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Q 1 is as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I) or in the sixth set of values of the variables of Structural Formula (II).
  • Ring A is a C7-C1 0 bridged, carbocyclic group; and R 12 , R 13 , and R 14 are each independently -H, and R 15 is -H or Ci alkyl; or ii) Ring A and R 15 , Ring A and R 14 , or Ring A and R 13 independently form an optionally substituted, C7-C1 0 bridged, carbocyclic group; and R is -H.
  • R 12 , R 13 , R 14 , R 15 , and x are each independently as described above in any one of the first through tenth sets of values of the variables of Structural Formula (II).
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Q 1 is as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I) or in the sixth set of values of the variables of Structural Formula (II).
  • Ring T-Q ⁇ R 2 is:
  • Each of rings A1-A4 is independently a C7-C1 0 bridged, carbocyclic ring optionally further substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, C1-C4 alkyl, C 1 -C 4 haloalkyl, and -0(Ci-C 4 alkyl).
  • Each of rings A5-A6 is independently and optionally further substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, C3-C5 cycloalkyl, and -0(Ci-C 4 alkyl).
  • Each R 14 is independently -H, C1-C4 alkyl, or C1-C4 haloalkyl.
  • R 12 and R 15 are each and independently -H, hydroxy, C1-C4 alkyl, or C1-C4 haloalkyl.
  • R 21 , R 22 , R 23 , R 24 , and R 25 are each independently -H, -F, hydroxy, -0(Ci-C 4 alkyl), C1-C4 alkyl, or C1-C4 haloalkyl.
  • Each p is independently 1, 2, or 3. In one aspect, each of p is independently 2.
  • Each q is independently 0, 1 or 2. In one aspect, each of q is independently 1.
  • Each r is independently 1 or 2.
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Q 1 is as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I) or in the sixth set of values of the variables of Structural Formula (II).
  • Ring T-Q x -R 2 is as described above in the twelfth set of values of the variables of Structural Formula (II).
  • R 12 , R 14 and R 15 are each independently -H or C1-C4 alkyl.
  • R , R , R , and R are each independently -H or C1-C4 alkyl.
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Q 1 is independently -C(0)0-, -NHC(O)-, or -NHC(0)NR'-.
  • Ring T-Q ⁇ R 2 , R 12 , R 14 , R 15 , R 21 , R 22 , R 23 , R 24 , and R 25 are each independently as described above in any one of the first through the thirteenth set of values of the variables of Structural Formula (II).
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • R 2 is independently -H, an optionally substituted C1-C6 alkyl, an optionally substituted 5-7 membered heterocyclic group, an optionally substituted phenyl group, or an optionally substituted 5-6 membered heteroaryl group; or optionally R 2 and R', together with the nitrogen atom to which they are attached, form an optionally substituted, 5-7 membered heterocyclic group; wherein said C1-C6 alkyl is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, and -0(Ci-C 4 alkyl); and each of said heterocyclic, phenyl and heteroaryl groups is independently and optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, C1-C4 alkyl, C1-C4 haloalkyl, and -0(Ci-C 4 alkyl).
  • R 2 is H, optionally substituted Ci_6 alkyl, optionally substituted 5-6 membered heterocyclic, or optionally substituted 5-6 membered hereroaryl. In another aspect, R 2 is H or optionally substituted Ci_6 alkyl. In yet another aspect, R 2 is H, optionally substituted 5-6 membered heterocyclic, or optionally substituted 5-6 membered heteroaryl.
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • R 2 is H or optionally substituted Ci_6 alkyl; and R 12 , R 14 , R 15 , R 21 , R 22 , R 23 , R 24 , and R 25 are each independently -H.
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Z 1 is CH.
  • X 1 is -CI.
  • X 2 is -F.
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • the compounds of the invention are represented by any one of Structural Formulae (III) - (V), or pharmaceutically acceptable salts thereof:
  • ring P is a C3-C6 carbocyclic ring, and values of the other variables of Structural
  • Formulae (III) - (V) are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Z 2 is CH.
  • R 3 is -C(0)OR, -OH, -CH 2 OH, -S(0) 2 R 9 , or -S(0) 2 -NRR 10 .
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Z 2 and R 3 are each independently as described above in any one of the first set through the sixth set of values of the variables of Structural Formulae (III) - (V).
  • R 4 , R 5 , and R 6 are each and independently -CH 3 , -CH2F, -CF 3 , or -C2H5; or
  • R 4 is -CH 3 , -CH2F, -CF 3 , or -C2H5; and R 5 and R 6 together with the carbon atom to which they are attached form a C 3 -C6 carbocyclic ring.
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Z 2 , R 3 , R 4 , R 5 , and R 6 are each and independently as described above in any one of the first set through the seventh set of values of the variables of Structural Formulae (III) - (V).
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Q 2 , Z 2 , R 3 , R 4 , R 5 , and R 6 are each and independently as described above in any one of the first set through the eighth set of values of the variables of Structural Formulae (III) - (V).
  • R is -H or Ci-4 alkyl.
  • R 9 is -OH.
  • R 10 is Ci-4 alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, -OR and -C(0)OR.
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Q 2 , Z 2 , R, R 4 R 5 , R 6 , R 9 , and R 10 are each and independently as described above in any one of the first set through the ninth set of values of the variables of Structural Formulae (III) - (V).
  • R 3 is -C(0)OR, -S(0) 2 R 9 , or -S(0) 2 -NRR 10 .
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • Q 2 , Z 2 , R, R 4 , R 3 , R 5 , R 6 , R 9 , and R 10 are each and independently as described above in any one of the first set through the tenth set of values of the variables of Structural Formulae (III) - (V).
  • Z 1 is CH.
  • X 1 is -CI.
  • X 2 is -F.
  • Values of the other variables are each and independently as described above in any one of the first through fifth sets of values of the variables of Structural Formula (I).
  • the compounds of the invention are represented by any one of Structural Formulae (I) - (V) or a pharmaceutically acceptable salt thereof, wherein values of the variables are each and independently as shown in the compounds of Table 1.
  • the compounds of the invention are represented by any one of the structural formulae depicted in Table 1, or a pharmaceutically acceptable salt thereof.
  • the compounds of the invention described herein can be prepared by any suitable method known in the art. For example, they can be prepared in accordance with procedures described in WO 2005/095400, WO 2007/084557, WO 2010/01 1768, WO 2010/01 1756, WO 2010/011772, WO 2009/073300, and PCT/US2010/038988 filed on June 17, 2010.
  • the compounds shown in Table 1 can be prepared by any suitable method known in the art, for example, WO 2005/095400, WO 2007/084557, WO 2010/011768, WO
  • the present invention provides methods of preparing a compound represented by any one of Structural Formulae (I) - (V).
  • the compounds of the invention can be prepared as depicted in General Scheme 1. Any suitable condition known in the art can be employed in the invention for each step depicted in the scheme.
  • the methods comprise reacting Compound (A) with Compound (B) under suitable conditions to form a compound of Structural Formula (XX), wherein each of L 1 and L 2 independently is a halogen (F, CI, Br, or I), G is trityl and the remaining variables of Compounds (A), (B) and Structural Formula (XX) are each and independently as described above for Structural Formulae (I) - (V).
  • XX Structural Formula
  • Typical examples for L 1 and L 2 are each and independently CI or Br.
  • the methods further comprise deprotecting the G group under suitable conditions to form the compounds of Structural Formula (I).
  • Any suitable condition known in the art can be employed in the invention for each step depicted in the scheme.
  • any suitable condition described in WO 2005/095400 and WO 2007/084557 for the coupling of a dioxaboraolan with, for example, a chloro-pyrimidine can be employed for the reaction between Compounds (A) and (B).
  • the reaction between compounds (A) and (B) can be performed in the presence of Pd(PPh 3 ) 4 or Pd2(dba) 3 (dba is dibenzylidene acetone).
  • the de- tritylation step can be performed under an acidic condition (e.g., trifluoroacetic acid (TFA)) in the presence of, for example, EtsSiH (Et is ethyl).
  • an acidic condition e.g., trifluoroacetic acid (TFA)
  • EtsSiH Et is ethyl
  • the method further comprises the step of preparing Compound (A) by reacting Compound (E) with Compound (D).
  • Any suitable conditions know in the art can be employed in this step, and Compounds (E) and (D) can be prepared by any suitable method known in the art. Specific exemplary conditions are described in the Exemplification below. Compounds (E) and (D) can be prepared by any suitable method known in the art. Specific exemplary synthetic methods of these compounds are described below in the
  • the present invention is directed to a compound represented by Structural Formula (XX), wherein the variables of Structural Formula (XX) are each and independently as defined in any one of the claims, and G is trityl.
  • XX Structural Formula
  • Specific examples of the compounds represented by Structural formula (XX) are shown below in the Exemplification. Some specific examples include: Compounds 11a, 19a, and 42a, which are shown in the Exemplification below.
  • compounds of the invention may optionally be substituted with one or more substituents, such as illustrated generally below, or as exemplified by particular classes, subclasses, and species of the invention.
  • substituents such as illustrated generally below, or as exemplified by particular classes, subclasses, and species of the invention.
  • the phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.”
  • substituted refers to the replacement of one or more hydrogen radicals in a given structure with the radical of a specified substituent.
  • an optionally substituted group may have a substituent at each substitutable position of the group.
  • substituent When more than one position in a given structure can be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at each position. When the term “optionally substituted” precedes a list, said term refers to all of the subsequent substitutable groups in that list. If a substituent radical or structure is not identified or defined as “optionally substituted", the substituent radical or structure is unsubstituted. For example, if X is optionally substituted Ci.Csalkyl or phenyl; X may be either optionally substituted C1-C3 alkyl or optionally substituted phenyl.
  • up to refers to zero or any integer number that is equal or less than the number following the phrase.
  • up to 3 means any one of 0, 1, 2, and 3.
  • a specified number range of atoms includes any integer therein. For example, a group having from 1-4 atoms could have 1, 2, 3, or 4 atoms.
  • a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week. Only those choices and
  • aliphatic or "aliphatic group”, as used herein, means a straight- chain (i.e., unbranched), or branched, hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation but is non-aromatic. Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1 -4 aliphatic carbon atoms.
  • Aliphatic groups may be linear or branched, substituted or unsubstituted alkyl, alkenyl, or alkynyl groups. Specific examples include, but are not limited to, methyl, ethyl, isopropyl, n-propyl, sec -butyl, vinyl, n-butenyl, ethynyl, and tert-butyl and acetylene.
  • alkyl as used herein means a saturated straight or branched chain hydrocarbon.
  • alkenyl as used herein means a straight or branched chain hydrocarbon comprising one or more double bonds.
  • alkynyl as used herein means a straight or branched chain hydrocarbon comprising one or more triple bonds.
  • Each of the "alkyl”, “alkenyl” or “alkynyl” as used herein can be optionally substituted as set forth below.
  • the "alkyl” is Ci-Ce alkyl or C1-C4 alkyl.
  • the "alkenyl” is C2-C6 alkenyl or C2-C4 alkenyl.
  • the "alkynyl” is C2-C6 alkynyl or C2-C4 alkynyl.
  • cycloaliphatic refers to a non-aromatic carbon only containing ring system which can be saturated or contains one or more units of unsaturation, having three to fourteen ring carbon atoms. In some embodiments, the number of carbon atoms is 3 to 10. In other embodiments, the number of carbon atoms is 4 to 7. In yet other embodiments, the number of carbon atoms is 5 or 6.
  • the term includes monocyclic, bicyclic or polycyclic, fused, spiro or bridged carbocyclic ring systems.
  • the term also includes polycyclic ring systems in which the carbocyclic ring can be "fused" to one or more non-aromatic carbocyclic or heterocyclic rings or one or more aromatic rings or combination thereof, wherein the radical or point of attachment is on the carbocyclic ring.
  • "Fused" bicyclic ring systems comprise two rings which share two adjoining ring atoms.
  • Bridged bicyclic group comprise two rings which share three or four adjacent ring atoms.
  • Spiro bicyclic ring systems share one ring atom.
  • Examples of cycloaliphatic groups include, but are not limited to, cycloalkyl and
  • cycloalkenyl groups include, but are not limited to, cyclohexyl, cyclopropenyl, and cyclobutyl.
  • heterocycle refers to a non-aromatic ring system which can be saturated or contain one or more units of unsaturation, having three to fourteen ring atoms in which one or more ring carbons is replaced by a heteroatom such as, N, S, or O and each ring in the system contains 3 to 7 members.
  • non-aromatic heterocyclic rings comprise up to three heteroatoms selected from N, S and O within the ring.
  • non-aromatic heterocyclic rings comprise up to two heteroatoms selected from N, S and O within the ring system.
  • non-aromatic heterocyclic rings comprise up to two heteroatoms selected from N and O within the ring system.
  • the term includes monocyclic, bicyclic or polycyclic fused, spiro or bridged heterocyclic ring systems.
  • the term also includes polycyclic ring systems in which the heterocyclic ring can be fused to one or more non-aromatic carbocyclic or heterocyclic rings or one or more aromatic rings or combination thereof, wherein the radical or point of attachment is on the heterocyclic ring.
  • heterocycles include, but are not limited to, piperidinyl, piperizinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, azepanyl, diazepanyl, triazepanyl, azocanyl, diazocanyl, triazocanyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, oxazocanyl, oxazepanyl, thiazepanyl, thiazocanyl, benzimidazolonyl, tetrahydrofuranyl,
  • aryl (or "aryl ring” or “aryl group”) used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl” refers to carbocyclic aromatic ring systems.
  • aryl may be used interchangeably with the terms “aryl ring” or “aryl group”.
  • Carbocyclic aromatic ring groups have only carbon ring atoms (typically six to fourteen) and include monocyclic aromatic rings such as phenyl and fused polycyclic aromatic ring systems in which two or more carbocyclic aromatic rings are fused to one another. Examples include 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl.
  • Carbocyclic aromatic ring or “carbocyclic aromatic”, as it is used herein, is a group in which an aromatic ring is “fused” to one or more non- aromatic rings (carbocyclic or heterocyclic), such as in an indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic ring.
  • heteroaryl refers to heteroaromatic ring groups having five to fourteen members, including monocyclic heteroaromatic rings and polycyclic aromatic rings in which a monocyclic aromatic ring is fused to one or more other aromatic ring.
  • Heteroaryl groups have one or more ring heteroatoms.
  • heteroaryl is a group in which an aromatic ring is "fused” to one or more non-aromatic rings (carbocyclic or heterocyclic), where the radical or point of attachment is on the aromatic ring.
  • Bicyclic 6,5 heteroaromatic ring as used herein, for example, is a six membered heteroaromatic ring fused to a second five membered ring, wherein the radical or point of attachment is on the six membered ring.
  • heteroaryl groups include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl or thiadiazolyl including, for example, 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4- imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl, 5- oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 3 -pyrazolyl, 4-pyrazolyl, 1 -pyrrolyl, 2- pyrrolyl, 3 -pyrrolyl, 2-pyri
  • cyclo include mono-, bi-, polycyclic, fused, spiro, or bridged ring systems including cycloaliphatic, heterocycloaliphatic, carbocyclic aryl, or heteroaryl, each of which has been previously defined.
  • a "bicyclic ring system” includes 8-12 (e.g., 9, 10, or 11) membered structures that form two rings, wherein the two rings have at least one atom in common (e.g., 2 atoms in common).
  • Bicyclic ring systems include bicycloaliphatics (e.g., bicycloalkyl or bicycloalkenyl), bicycloheteroaliphatics, bicyclic carbocyclic aryls, and bicyclic heteroaryls.
  • bridged bicyclic ring system refers to a bicyclic heterocycloalipahtic ring system or bicyclic cycloaliphatic ring system in which the rings are bridged.
  • bridged bicyclic ring systems include, but are not limited to, adamantanyl, norbornanyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.2.3]nonyl, 2-oxa-bicyclo[2.2.2]octyl, l-aza-bicyclo[2.2.2]octyl, 3-aza- bicyclo[3.2.1]octyl, and 2,6-dioxa-tricyclo[3.3.1.03,7]nonyl.
  • a bridged bicyclic ring system can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, carbocyclic aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, (carbocyclic aryl)oxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, nitro, carboxy, alkoxycarbonyl,
  • substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalky
  • alkylcarbonyloxy aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino
  • heteroarylcarbonylamino heteroaralkylcarbonylamino, cyano, halo, hydroxy, acyl, mercapto, alkylsulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
  • bridge refers to a bond or an atom or an unbranched chain of atoms connecting two different parts of a molecule.
  • the two atoms that are connected through the bridge (usually but not always, two tertiary carbon atoms) are denotated as “bridgeheads”.
  • spiro refers to ring systems having one atom (usually a quaternary carbon) as the only common atom between two rings.
  • ring atom is an atom such as C, N, O or S that is in the ring of an aromatic group, cycloalkyl group or non-aromatic heterocyclic ring.
  • a "substitutable ring atom" in an aromatic group is a ring carbon or nitrogen atom bonded to a hydrogen atom.
  • the hydrogen can be optionally replaced with a suitable substituent group.
  • substituted ring atom does not include ring nitrogen or carbon atoms which are shared when two rings are fused.
  • substituted ring atom does not include ring carbon or nitrogen atoms when the structure depicts that they are already attached to a moiety other than hydrogen.
  • heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
  • an optionally substituted aralkyl can be substituted on both the alkyl and the aryl portion. Unless otherwise indicated as used herein optionally substituted aralkyl is optionally substituted on the aryl portion.
  • each R * is independently selected from hydrogen or an optionally substituted Ci_6 aliphatic.
  • Optional substituents on the aliphatic group of R are selected from NH 2 , NH(Ci_ 4 aliphatic), N(Ci_ 4 aliphatic) 2 , halogen, Ci_ 4 aliphatic, OH, 0(Ci_ 4 aliphatic), O 2 , CN, CO 2 H, C0 2 (Ci_ 4 aliphatic), 0(halo Ci_ 4 aliphatic), or halo(Ci_ 4 aliphatic), wherein each of the foregoing Ci_ 4 aliphatic groups of R is unsubstituted.
  • optional substituents on the nitrogen of a heterocyclic ring include those used above.
  • Optional substituents on the aliphatic group or the phenyl ring of R + are selected from NH 2 , NH(Ci_ 4 aliphatic), N(Ci_ 4 aliphatic) 2 , halogen, Ci_ 4 aliphatic, OH, 0(Ci_ 4 aliphatic), N0 2 , CN, C0 2 H, C0 2 (Ci_ 4 aliphatic), 0(halo Ci_ 4 aliphatic), or halo(Ci_ 4 aliphatic), wherein each of the foregoing Ci_ 4 aliphatic groups of R + is unsubstituted.
  • an aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents. Suitable substituents on the unsaturated carbon atom of a carbocyclic aryl or heteroaryl group are selected from those listed above. Other suitable substituents include: halogen; -R°; -OR°; -SR°; 1,2-methylenedioxy; 1,2-ethylenedioxy; phenyl (Ph) optionally substituted with R°; -O(Ph) optionally substituted with R°;
  • Optional substituents on the aliphatic group of R° are selected from NH 2 , NH(Ci-4aliphatic), N(Ci-4aliphatic) 2 , halogen, Ci-4aliphatic, OH, 0(Ci- 4 aliphatic), N0 2 , CN, C0 2 H, C0 2 (Ci_ 4 aliphatic), 0(haloCi_ 4 aliphatic), or haloCi_ 4 aliphatic, CHO, N(CO)(Ci_4 aliphatic), C(0)N(Ci_ 4 aliphatic), wherein each of the foregoing Ci_ 4 aliphatic groups of R° is unsubstituted.
  • Non-aromatic nitrogen containing heterocyclic rings that are substituted on a ring nitrogen and attached to the remainder of the molecule at a ring carbon atom are said to be N substituted.
  • an N alkyl piperidinyl group is attached to the remainder of the molecule at the two, three or four position of the piperidinyl ring and substituted at the ring nitrogen with an alkyl group.
  • Non-aromatic nitrogen containing heterocyclic rings such as pyrazinyl that are substituted on a ring nitrogen and attached to the remainder of the molecule at a second ring nitrogen atom are said to be N' substituted-N-heterocycles.
  • an N' acyl N-pyrazinyl group is attached to the remainder of the molecule at one ring nitrogen atom and substituted at the second ring nitrogen atom with an acyl group.
  • two independent occurrences of R° may be taken together with the atom(s) to which each variable is bound to form a 5-8-membered heterocyclyl, carbocyclic aryl, or heteroaryl ring or a 3-8-membered cycloalkyl ring.
  • Exemplary rings that are formed when two independent occurrences of R° (or R + , or any other variable similarly defined herein) are taken together with the atom(s) to which each variable is bound include, but are not limited to the following: a) two independent occurrences of R° (or R + , or any other variable similarly defined herein) that are bound to the same atom and are taken together with that atom to form a ring, for example, N(R°) 2 , where both occurrences of R° are taken together with the nitrogen atom to form a piperidin-l-yl, piperazin- 1 -yl, or morpholin-4-yl group; and b) two independent occurrences of R° (or R + , or any other variable similarly defined herein) that are bound to different atoms and are taken together with both of those atoms to form a ring, for
  • hydroxyl'Or hydroxy or “alcohol moiety” refers to -OH.
  • an "alkoxycarbonyl,” which is encompassed by the term carboxy, used alone or in connection with another group refers to a group such as
  • a "carbonyl” refers to -C(O)-.
  • alkoxy refers to an alkyl group, as previously defined, attached to the molecule through an oxygen (“alkoxy” e.g., -O-alkyl) or sulfur (“alkylthio” e.g., -S-alkyl) atom.
  • halogen means F, CI, Br, or I.
  • cyano or "nitrile” refer to -CN or -C ⁇ N.
  • alkoxyalkyl alkoxyalkenyl
  • alkoxyaliphatic alkoxyaliphatic
  • alkoxyalkoxy mean alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more alkoxy groups.
  • haloalkyl mean alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more halogen atoms.
  • This term includes perfluorinated alkyl groups, such as -CF 3 and -CF 2 CF 3 .
  • cyanoalkoxy mean alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more cyano groups. In some embodiments, the cyanoalkyl is ( C)-alkyl-.
  • aminoalkyl aminoalkenyl
  • aminoaliphatic aminoalkyl
  • aminoalkoxy mean alkyl, alkenyl, aliphatic or alkoxy, as the case may be, substituted with one or more amino groups, wherein the amino group is as defined above.
  • aminoaliphatic is a C1-C6 aliphatic group substituted with one or more - H2 groups.
  • aminoalkyl refers to the structure (R x R Y )N-alkyl-, wherein each of R x and R Y independently is as defined above.
  • the aminoalkyl is C1-C6 alkyl substituted with one or more -NH2 groups.
  • the aminoalkenyl is C1-C6 alkenyl substituted with one or more - H2 groups.
  • the aminoalkoxy is -0(C1-C6 alkyl) wherein the alkyl group is substituted with one or more -NH 2 groups.
  • hydroxyalkyl means alkyl, aliphatic or alkoxy, as the case may be, substituted with one or more -OH groups.
  • alkoxyalkyl means alkyl, aliphatic or alkoxy, as the case may be, substituted with one or more alkoxy groups.
  • alkoxyalkyl refers to an alkyl group such as (alkyl-O)-alkyl-, wherein alkyl is as defined above.
  • carboxyalkyl means alkyl substituted with one or more carboxy groups, wherein alkyl and carboxy are as defined above.
  • a protecting group and “protective group” as used herein, are interchangeable and refer to an agent used to temporarily block one or more desired functional groups in a compound with multiple reactive sites.
  • a protecting group has one or more, or specifically all, of the following characteristics: a) is added selectively to a functional group in good yield to give a protected substrate that is b) stable to reactions occurring at one or more of the other reactive sites; and c) is selectively removable in good yield by reagents that do not attack the regenerated, deprotected functional group. As would be understood by one skilled in the art, in some cases, the reagents do not attack other reactive groups in the compound.
  • the reagents may also react with other reactive groups in the compound.
  • protecting groups are detailed in Greene, T. W., Wuts, P. G in "Protective Groups in Organic Synthesis", Third Edition, John Wiley & Sons, New York: 1999 (and other editions of the book), the entire contents of which are hereby incorporated by reference.
  • the term "nitrogen protecting group”, as used herein, refers to an agent used to temporarily block one or more desired nitrogen reactive sites in a multifunctional compound.
  • Preferred nitrogen protecting groups also possess the characteristics exemplified for a protecting group above, and certain exemplary nitrogen protecting groups are also detailed in Chapter 7 in Greene, T.W., Wuts, P. G in "Protective Groups in Organic Synthesis", Third Edition, John Wiley & Sons, New York: 1999, the entire contents of which are hereby incorporated by reference.
  • the term "displaceable moiety” or “leaving group” refers to a group that is associated with an aliphatic or aromatic group as defined herein and is subject to being displaced by nucleophilic attack by a nucleophile.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, cis-trans, conformational, and rotational) forms of the structure.
  • isomeric e.g., enantiomeric, diastereomeric, cis-trans, conformational, and rotational
  • the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers are included in this invention, unless only one of the isomers is drawn specifically.
  • a substituent can freely rotate around any rotatable
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools or probes in biological assays.
  • Such compounds, especially deuterium analogs can also be therapeutically useful.
  • the compounds of the invention are defined herein by their chemical structures and/or chemical names. Where a compound is referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.
  • the compounds described herein can exist in free form, or, where appropriate, as salts. Those salts that are pharmaceutically acceptable are of particular interest since they are useful in administering the compounds described below for medical purposes. Salts that are not pharmaceutically acceptable are useful in manufacturing processes, for isolation and purification purposes, and in some instances, for use in separating stereoisomeric forms of the compounds of the invention or intermediates thereof.
  • the term "pharmaceutically acceptable salt” refers to salts of a compound which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue side effects, such as, toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • acid addition salts can be prepared by 1) reacting the purified compound in its free-base form with a suitable organic or inorganic acid and 2) isolating the salt thus formed.
  • acid addition salts might be a more convenient form for use and use of the salt amounts to use of the free basic form.
  • Examples of pharmaceutically acceptable, non-toxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, glycolate, gluconate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, ox
  • base addition salts can be prepared by 1) reacting the purified compound in its acid form with a suitable organic or inorganic base and 2) isolating the salt thus formed.
  • base addition salt might be more convenient and use of the salt form inherently amounts to use of the free acid form.
  • Salts derived from appropriate bases include alkali metal (e.g., sodium, lithium, and potassium), alkaline earth metal (e.g., magnesium and calcium), ammonium and + (Ci_4alkyl)4 salts.
  • This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
  • Basic addition salts include pharmaceutically acceptable metal and amine salts.
  • Suitable metal salts include the sodium, potassium, calcium, barium, zinc, magnesium, and aluminium. The sodium and potassium salts are usually preferred. Further
  • pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.
  • Suitable inorganic base addition salts are prepared from metal bases which include sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide and the like.
  • Suitable amine base addition salts are prepared from amines which are frequently used in medicinal chemistry because of their low toxicity and acceptability for medical use.
  • the compounds described herein can also exist as pharmaceutically acceptable solvates (e.g., hydrates) and clathrates.
  • pharmaceutically acceptable solvate is a solvate formed from the association of one or more pharmaceutically acceptable solvent molecules to one of the compounds described herein.
  • solvate includes hydrates (e.g., hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate, and the like).
  • hydrate means a compound described herein or a salt thereof that further includes a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.
  • clathrate means a compound described herein or a salt thereof in the form of a crystal lattice that contains spaces (e.g., channels) that have a guest molecule (e.g., a solvent or water) trapped within.
  • compositions to treat or prevent the herein identified disorders.
  • a "pharmaceutically acceptable derivative or prodrug” includes any pharmaceutically acceptable ester, salt of an ester or other derivative or salt thereof of a compound described herein which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound described herein or an inhibitorily active metabolite or residue thereof.
  • Particularly favoured derivatives or prodrugs are those that increase the bioavailability of the compounds when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
  • prodrug means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (in vitro or in vivo) to provide a compound described herein. Prodrugs may become active upon such reaction under biological conditions, or they may have activity in their unreacted forms.
  • prodrugs contemplated in this invention include, but are not limited to, analogs or derivatives of compounds of the invention that comprise biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues.
  • biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues.
  • Other examples of prodrugs include derivatives of compounds described herein that comprise -NO, -N0 2 , -ONO, or -ONO 2 moieties.
  • Prodrugs can typically be prepared using well-known methods, such as those described by BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY (1995) 172-178, 949-982 (Manfred E. Wolff ed., 5th ed).
  • a "pharmaceutically acceptable derivative” is an adduct or derivative which, upon administration to a patient in need, is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
  • pharmaceutically acceptable derivatives include, but are not limited to, esters and salts of such esters.
  • Pharmaceutically acceptable prodrugs of the compounds described herein include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.
  • One aspect of the present invention is generally related to the use of the compounds described herein or pharmaceutically acceptable salts, or pharmaceutically acceptable compositions comprising such a compound or a pharmaceutically acceptable salt thereof, for inhibiting the replication of influenza viruses in a biological sample or in a patient, for reducing the amount of influenza viruses (reducing viral titer) in a biological sample or in a patient, and for treating influenza in a patient.
  • the present invention is generally related to the use of compounds represented by any one of Structural Formulae (I) - (V), or pharmaceutically acceptable salts thereof for any of the uses specified above:
  • the present invention is directed to the use of any compound selected from the compounds depicted in Table 1 or a pharmaceutically acceptable salt thereof, for any of the uses described above.
  • the compounds are represented by any one of
  • the compounds described herein or pharmaceutically acceptable salts thereof can be used to reduce viral titre in a biological sample (e.g. an infected cell culture) or in humans (e.g. lung viral titre in a patient).
  • Influenza as used herein, are used interchangeable to mean the disease caused by an infection with an influenza virus.
  • Influenza is an infectious disease that affects birds and mammals caused by influenza viruses.
  • Influenza viruses are RNA viruses of the family Orthomyxoviridae, which comprises five genera: Influenzavirus A, Influenzavirus B, Influenzavirus C, Isavirus and Thogotovirus.
  • Influenzavirus A genus has one species, influenza A virus which can be subdivided into different serotypes based on the antibody response to these viruses: H1 1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2 , H7N3 and H10N7.
  • Influenzavirus B genus has one species, influenza B virus. Influenza B almost exclusively infects humans and is less common than influenza A.
  • Influenzavirus C genus has one species, Influenzavirus C virus, which infects humans and pigs and can cause severe illness and local epidemics.
  • Influenzavirus C is less common than the other types and usually seems to cause mild disease in children.
  • influenza or influenza viruses are associated with Influenzavirus A or B. In some embodiments of the invention, influenza or influenza viruses are associated with Influenzavirus A. In some specific embodiments of the invention, Influenzavirus A is H1 1, H2N2, H3N2 or H5 1.
  • influenza In humans, common symptoms of influenza are chills, fever, pharyngitis, muscle pains, severe headache, coughing, weakness, and general discomfort. In more serious cases, influenza causes pneumonia, which can be fatal, particularly in young children and the elderly. Although it is often confused with the common cold, influenza is a much more severe disease and is caused by a different type of virus. Influenza can produce nausea and vomiting, especially in children, but these symptoms are more characteristic of the unrelated gastroenteritis, which is sometimes called "stomach flu" or "24-hour flu”.
  • Symptoms of influenza can start quite suddenly one to two days after infection. Usually the first symptoms are chills or a chilly sensation, but fever is also common early in the infection, with body temperatures ranging from 38-39 °C
  • Symptoms of influenza may include: body aches, especially joints and throat, extreme coldness and fever, fatigue, Headache, irritated watering eyes, reddened eyes, skin (especially face), mouth, throat and nose, abdominal pain (in children with influenza B). Symptoms of influenza are non-specific, overlapping with many pathogens ("influenza-like illness).
  • influenza virus mediated medical or pathological condition
  • the terms “subject” and “patient” are used interchangeably.
  • the terms “subject” and “patient” refer to an animal (e.g., a bird such as a chicken, quail or turkey, or a mammal), specifically a “mammal” including a non-primate (e.g., a cow, pig, horse, sheep, rabbit, guinea pig, rat, cat, dog, and mouse) and a primate (e.g., a monkey, chimpanzee and a human), and more specifically a human.
  • a non-primate e.g., a cow, pig, horse, sheep, rabbit, guinea pig, rat, cat, dog, and mouse
  • a primate e.g., a monkey, chimpanzee and a human
  • the subject is a non-human animal such as a farm animal (e.g., a horse, cow, pig or sheep), or a pet (e.g., a dog, cat, guinea pig or rabbit).
  • a farm animal e.g., a horse, cow, pig or sheep
  • a pet e.g., a dog, cat, guinea pig or rabbit
  • the subject is a "human”.
  • biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • multiplicity of infection is the ratio of infectious agents (e.g. phage or virus) to infection targets (e.g. cell).
  • infectious agents e.g. phage or virus
  • infection targets e.g. cell
  • multiplicity of infection or MOI is the ratio defined by the number of infectious virus particles deposited in a well divided by the number of target cells present in that well.
  • the term "inhibition of the replication of influenza viruses” includes both the reduction in the amount of virus replication (e.g. the reduction by at least 10 %) and the complete arrest of virus replication (i.e., 100% reduction in the amount of virus replication). In some embodiments, the replication of influenza viruses are inhibited by at least 50%, at least 65%, at least 75%, at least 85%, at least 90%, or at least 95%.
  • Influenza virus replication can be measured by any suitable method known in the art.
  • influenza viral titre in a biological sample e.g. an infected cell culture
  • humans e.g. lung viral titre in a patient
  • virus is added to the culture in the presence or absence of a test agent, and after a suitable length of time a virus-dependent endpoint is evaluated.
  • test agent e.g. an infected cell culture
  • virus-dependent endpoint e.g. the Madin-Darby canine kidney cells (MDCK) and the standard tissue culture adapted influenza strain, A/Puerto Rico/8/34 can be used.
  • MDCK Madin-Darby canine kidney cells
  • A/Puerto Rico/8/34 can be used.
  • a first type of cell assay that can be used in the invention depends on death of the infected target cells, a process called cytopathic effect (CPE), where virus infection causes exhaustion of the cell resources and eventual lysis of the cell.
  • CPE cytopathic effect
  • a low fraction of cells in the wells of a microtiter plate are infected (typically 1/10 to 1/1000), the virus is allowed to go through several rounds of replication over 48-72 hours, then the amount of cell death is measured using a decrease in cellular ATP content compared to uninfected controls.
  • a second type of cell assay that can be employed in the invention depends on the
  • RNA levels being directly measured using the branched-chain DNA hybridization method (bDNA).
  • bDNA branched-chain DNA hybridization method
  • a low number of cells are initially infected in wells of a microtiter plate, the virus is allowed to replicate in the infected cells and spread to additional rounds of cells, then the cells are lysed and viral RNA content is measured. This assay is stopped early, usually after 18-36 hours, while all the target cells are still viable. Viral RNA is quantitated by hybridization to specific oligonucleotide probes fixed to wells of an assay plate, then amplification of the signal by hybridization with additional probes linked to a reporter enzyme.
  • a "viral titer (or titre)" is a measure of virus concentration. Titer testing can employ serial dilution to obtain approximate quantitative information from an analytical procedure that inherently only evaluates as positive or negative. The titer corresponds to the highest dilution factor that still yields a positive reading; for example, positive readings in the first 8 serial twofold dilutions translate into a titer of 1 :256. A specific example is viral titer. To determine the titer, several dilutions will be prepared, such as 10 "1 , 10 "2 , 10 "3 ,..., 10 "8 . The lowest concentration of virus that still infects cells is the viral titer.
  • the terms “treat”, “treatment” and “treating” refer to both therapeutic and prophylactic treatments.
  • therapeutic treatments includes the reduction or amelioration of the progression, severity and/or duration of influenza viruses mediated conditions, or the amelioration of one or more symptoms (specifically, one or more discernible symptoms) of influenza viruses mediated conditions, resulting from the administration of one or more therapies (e.g., one or more therapeutic agents such as a compound or composition of the invention).
  • the therapeutic treatment includes the amelioration of at least one measurable physical parameter of an influenza virus mediated condition.
  • the therapeutic treatment includes the inhibition of the progression of an influenza virus mediated condition, either physically by, e.g., stabilization of a discernible symptom, physiologically by, e.g., stabilization of a physical parameter, or both.
  • the therapeutic treatment includes the reduction or stabilization of influenza viruses mediated infections.
  • Antiviral drugs can be used in the community setting to treat people who already have influenza to reduce the severity of symptoms and reduce the number of days that they are sick.
  • chemotherapy refers to the use of medications, e.g. small molecule drugs (rather than “vaccines”) for treating a disorder or disease.
  • medications e.g. small molecule drugs (rather than “vaccines”
  • vaccines small molecule drugs
  • prophylaxis or “prophylactic use” and “prophylactic treatment” as used herein, refer to any medical or public health procedure whose purpose is to prevent, rather than treat or cure a disease.
  • the terms “prevent”, “prevention” and “preventing” refer to the reduction in the risk of acquiring or developing a given condition, or the reduction or inhibition of the recurrence or said condition in a subject who is not ill, but who has been or may be near a person with the disease.
  • chemoprophylaxis refers to the use of medications, e.g. small molecule drugs (rather than "vaccines”) for the prevention of a disorder or disease.
  • prophylactic use includes the use in situations in which an outbreak has been detected, to prevent contagion or spread of the infection in places where a lot of people that are at high risk of serious influenza complications live in close contact with each other (e.g. in a hospital ward, daycare center, prison, nursing home, etc). It also includes the use among populations who require protection from the influenza but who either do not get protection after vaccination (e.g. due to weak immunse system), or when the vaccine is unavailable to them, or when they cannot get the vaccine because of side effects. It also includes use during the two weeks following vaccination, since during that time the vaccine is still ineffective.
  • Prophylactic use may also include treating a person who is not ill with the influenza or not considered at high risk for complications, in order to reduce the chances of getting infected with the influenza and passing it on to a high-risk person in close contact with him (for instance, healthcare workers, nursing home workers, etc).
  • an influenza "outbreak” is defined as a sudden increase of acute febrile respiratory illness (AFRI) occurring within a 48 to 72 hour period, in a group of people who are in close proximity to each other (e.g. in the same area of an assisted living facility, in the same household, etc) over the normal background rate or when any subject in the population being analyzed tests positive for influenza.
  • AFRI acute febrile respiratory illness
  • a “cluster” is defined as a group of three or more cases of AFRI occurring within a 48 to 72 hour period, in a group of people who are in close proximity to each other (e.g. in the same area of an assisted living facility, in the same household, etc).
  • index case is the initial patient in the population sample of an epidemiological investigation.
  • primary case or “patient zero” is the initial patient in the population sample of an epidemiological investigation.
  • the term is not capitalized.
  • the term is used to refer to a specific person in place of that person's name within a report on a specific investigation, the term is capitalized as Patient Zero.
  • Often scientists search for the index case to determine how the disease spread and what reservoir holds the disease in between outbreaks. Note that the index case is the first patient that indicates the existence of an outbreak. Earlier cases may be found and are labeled primary, secondary, tertiary, etc.
  • the methods of the invention are a preventative or "preemptive” measure to a patient, specifically a human, having a predisposition to complications resulting from infection by an influenza virus.
  • pre-emptive as used herein as for example in pre-emptive use, “pre-emptively”, etc, is the prophylactic use in situations in which an "index case” or an "outbreak" has been confirmed, in order to prevent the spread of infection in the rest of the community or population group.
  • the methods of the invention are applied as a "preemptive" measure to members of a community or population group, specifically humans, in order to prevent the spread of infection.
  • an "effective amount” refers to an amount sufficient to elicit the desired biological response.
  • the desired biological response is to inhibit the replication of influenza virus, to reduce the amount of influenza viruses or to reduce or ameliorate the severity, duration, progression, or onset of a influenza virus infection, prevent the advancement of an influenza viruses infection, prevent the recurrence, development, onset or progression of a symptom associated with an influenza virus infection, or enhance or improve the prophylactic or therapeutic effect(s) of another therapy used against influenza infections.
  • the precise amount of compound administered to a subject will depend on the mode of administration, the type and severity of the infection and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drugs.
  • an "effective amount" of the second agent will depend on the type of drug used. Suitable dosages are known for approved agents and can be adjusted by the skilled artisan according to the condition of the subject, the type of condition(s) being treated and the amount of a compound described herein being used. In cases where no amount is expressly noted, an effective amount should be assumed.
  • compounds described herein can be administered to a subject in a dosage range from between approximately 0.01 to 100 mg/kg body weight/day for therapeutic or prophylactic treatment.
  • dosage regimens can be selected in accordance with a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the renal and hepatic function of the subject; and the particular compound or salt thereof employed, the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • the skilled artisan can readily determine and prescribe the effective amount of the compounds described herein required to treat, to prevent, inhibit (fully or partially) or arrest the progress of the disease.
  • Dosages of the compounds described herein can range from between about
  • the total amount per day can be administered in a single dose or can be administered in multiple dosing, such as twice a day (e.g., every 12 hours), tree times a day (e.g., every 8 hours), or four times a day (e.g., every 6 hours).
  • onset of symptoms e.g., nasal congestion, sore throat, cough, aches, fatigue, headaches, and chills/sweats.
  • the therapeutic treatment can last for any suitable duration, for example, for 5 days, 7 days, 10 days, 14 days, etc.
  • the compounds described herein can be administered to a patient within, for example, 2 days of onset of symptoms in the index case, and can be continued for any suitable duration, for example, for 7 days, 10 days, 14 days, 20 days, 28 days, 35 days, 42 days, etc.
  • An effective amount can be achieved in the method or pharmaceutical composition of the invention employing a compound of the invention (including a pharmaceutically acceptable salt or solvate (e.g., hydrate)) alone or in combination with an additional suitable therapeutic agent, for example, an antiviral agent or a vaccine.
  • an additional suitable therapeutic agent for example, an antiviral agent or a vaccine.
  • an effective amount can be achieved using a first amount of a compound of the invention and a second amount of an additional suitable therapeutic agent (e.g. an antiviral agent or vaccine).
  • a compound of the invention and the additional therapeutic agent are each administered in an effective amount (i.e., each in an amount which would be therapeutically effective if administered alone).
  • a compound of the invention and the additional therapeutic agent are each administered in an amount which alone does not provide a therapeutic effect (a subtherapeutic dose).
  • a compound of the invention can be administered in an effective amount, while the additional therapeutic agent is administered in a sub-therapeutic dose.
  • a compound of the invention can be administered in a sub-therapeutic dose, while the additional therapeutic agent, for example, a suitable cancer-therapeutic agent is administered in an effective amount.
  • the terms “in combination” or “co-administration” can be used interchangeably to refer to the use of more than one therapy (e.g., one or more prophylactic and/or therapeutic agents).
  • therapy e.g., one or more prophylactic and/or therapeutic agents.
  • the use of the terms does not restrict the order in which therapies (e.g., prophylactic and/or therapeutic agents) are administered to a subject.
  • Coadministration encompasses administration of the first and second amounts of the compounds of the coadministration in an essentially simultaneous manner, such as in a single pharmaceutical composition, for example, capsule or tablet having a fixed ratio of first and second amounts, or in multiple, separate capsules or tablets for each.
  • coadministration also encompasses use of each compound in a sequential manner in either order.
  • the present invention is directed to methods of combination therapy for inhibiting Flu viruses replication in biological samples or patients, or for treating or preventing Influenza virus infections in patients using the compounds or pharmaceutical compositions of the invention.
  • pharmaceutical compositions of the invention also include those comprising an inhibitor of Flu virus replication of this invention in combination with an anti-viral compound exhibiting anti-Influenza virus activity.
  • Methods of use of the compounds and compositions of the invention also include combination of chemotherapy with a compound or composition of the invention, or with a combination of a compound or composition of this invention with another anti-viral agent and vaccination with a Flu vaccine.
  • the compounds are administered sufficiently close in time to have the desired therapeutic effect.
  • the period of time between each administration which can result in the desired therapeutic effect can range from minutes to hours and can be determined taking into account the properties of each compound such as potency, solubility, bioavailability, plasma half-life and kinetic profile.
  • a compound of the invention and the second therapeutic agent can be administered in any order within about 24 hours of each other, within about 16 hours of each other, within about 8 hours of each other, within about 4 hours of each other, within about 1 hour of each other or within about 30 minutes of each other.
  • a first therapy e.g., a prophylactic or therapeutic agent such as a compound of the invention
  • a first therapy can be administered prior to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second therapy (e.g., a prophylactic or therapeutic agent such as an anti-cancer agent) to a subject.
  • a second therapy e.g., a prophylactic or therapeutic agent such as an anti-cancer agent
  • the method of co-administration of a first amount of a compound of the invention and a second amount of an additional therapeutic agent can result in an enhanced or synergistic therapeutic effect, wherein the combined effect is greater than the additive effect that would result from separate administration of the first amount of a compound of the invention and the second amount of an additional therapeutic agent.
  • the term "synergistic” refers to a combination of a compound of the invention and another therapy (e.g., a prophylactic or therapeutic agent), which is more effective than the additive effects of the therapies.
  • a synergistic effect of a combination of therapies can permit the use of lower dosages of one or more of the therapies and/or less frequent administration of said therapies to a subject.
  • the ability to utilize lower dosages of a therapy (e.g., a prophylactic or therapeutic agent) and/or to administer said therapy less frequently can reduce the toxicity associated with the administration of said therapy to a subject without reducing the efficacy of said therapy in the prevention, management or treatment of a disorder.
  • a synergistic effect can result in improved efficacy of agents in the prevention, management or treatment of a disorder.
  • a synergistic effect of a combination of therapies e.g., a combination of prophylactic or therapeutic agents
  • both therapeutic agents can be administered so that the period of time between each administration can be longer (e.g. days, weeks or months).
  • Suitable methods include, for example, the Sigmoid-Emax equation (Holford, N.H.G. and Scheiner, L.B., Clin. Pharmacokinet. 6: 429-453 (1981)), the equation of Loewe additivity (Loewe, S. and Muischnek, FL, Arch. Exp. Pathol Pharmacol. 1 14: 313-326 (1926)) and the median-effect equation (Chou, T.C. and Talalay, P., Adv. Enzyme Regul. 22: 27-55 (1984)).
  • Each equation referred to above can be applied with experimental data to generate a corresponding graph to aid in assessing the effects of the drug combination.
  • the corresponding graphs associated with the equations referred to above are the concentration-effect curve, isobologram curve and combination index curve, respectively.
  • neuraminidase inhibitors such as oseltamivir (Tamiflu®) and Zanamivir (Rlenza®)
  • viral ion channel (M2 protein) blockers such as amantadine (Symmetrel®) and rimantadine (Flumadine®)
  • antiviral drugs described in WO 2003/015798, including T- 705 under development by Toyama Chemical of Japan.
  • the compounds described herein can be co-administered with a traditional influenza vaccine.
  • the compounds described herein can be formulated into pharmaceutical compositions that further comprise a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle.
  • the present invention relates to a pharmaceutical composition comprising a compound of the invention described above, and a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle.
  • the present invention is a pharmaceutical composition comprising an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent, adjuvant or vehicle.
  • Pharmaceutically acceptable carriers include, for example, pharmaceutical diluents, excipients or carriers suitably selected with respect to the intended form of administration, and consistent with conventional pharmaceutical practices.
  • an “effective amount” includes a “therapeutically effective amount” and a “prophylactically effective amount”.
  • therapeutically effective amount refers to an amount effective in treating and/or ameliorating an influenza virus infection in a patient infected with influenza.
  • prolactically effective amount refers to an amount effective in preventing and/or substantially lessening the chances or the size of influenza virus infection outbreak. Specific examples of effective amounts are described above in the section entitled Uses of Disclosed Compounds.
  • a pharmaceutically acceptable carrier may contain inert ingredients which do not unduly inhibit the biological activity of the compounds.
  • the pharmaceutically acceptable carriers should be biocompatible, e.g., non-toxic, non-inflammatory, non- immunogenic or devoid of other undesired reactions or side-effects upon the administration to a subject.
  • the pharmaceutically acceptable carrier, adjuvant, or vehicle includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable
  • compositions and known techniques for the preparation thereof are contemplated to be within the scope of this invention.
  • side effects encompasses unwanted and adverse effects of a therapy (e.g., a prophylactic or therapeutic agent). Side effects are always unwanted, but unwanted effects are not necessarily adverse. An adverse effect from a therapy (e.g., prophylactic or therapeutic agent) might be harmful or uncomfortable or risky.
  • Side effects include, but are not limited to fever, chills, lethargy, gastrointestinal toxicities (including gastric and intestinal ulcerations and erosions), nausea, vomiting, neurotoxicities, nephrotoxicities, renal toxicities (including such conditions as papillary necrosis and chronic interstitial nephritis), hepatic toxicities (including elevated serum liver enzyme levels), myelotoxicities (including leukopenia, myelosuppression, thrombocytopenia and anemia), dry mouth, metallic taste, prolongation of gestation, weakness, somnolence, pain (including muscle pain, bone pain and headache), hair loss, asthenia, dizziness, extra-pyramidal symptoms, akathisia, cardiovascular disturbances and sexual dysfunction.
  • Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as twin 80, phosphates, glycine, sorbic acid, or potassium sorbate), partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, or zinc salts), colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, methylcellulose, hydroxypropyl methylcellulose, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose
  • compositions described above can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include
  • Injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S. P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • the rate of compound release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • compositions for rectal or vaginal administration are specifically suppositories which can be prepared by mixing the compounds described herein with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar— agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active compounds can also be in microencapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound described herein include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention.
  • the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body.
  • Such dosage forms can be made by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes, but is not limited to, subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally, intraperitoneally or intravenously.
  • Sterile injectable forms of the compositions described herein may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • a long-chain alcohol diluent or dispersant such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions described herein may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers commonly used include, but are not limited to, lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • compositions described herein may be administered in the form of suppositories for rectal administration.
  • suppositories for rectal administration.
  • a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • suitable non-irritating excipient include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
  • compositions described herein may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically- transdermal patches may also be used.
  • the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2 octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, specifically, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as
  • compositions may be formulated in an ointment such as petrolatum.
  • compositions may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • the compounds for use in the methods of the invention can be formulated in unit dosage form.
  • unit dosage form refers to physically discrete units suitable as unitary dosage for subjects undergoing treatment, with each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, optionally in association with a suitable pharmaceutical carrier.
  • the unit dosage form can be for a single daily dose or one of multiple daily doses (e.g., about 1 to 4 or more times per day). When multiple daily doses are used, the unit dosage form can be the same or different for each dose.
  • the compounds disclosed herein can be prepared by any suitble method known in the art, for example, WO 2005/095400, WO 2007/084557, WO 2010/011768, WO 2010/011756, WP 2010/01 1772, WO 2009/073300, and PCT/US2010/038988 filed on June 17, 2010.
  • the compounds shown in Table 1 can be prepared by any suitble method known in the art, for example, WO 2005/095400, WO 2007/084557, WO
  • reaction mixture was diluted with Et 2 0, poured into aqueous saturated NaHCC ⁇ solution and partitioned. The aqueous phase was extracted with additional Et 2 0 and the combined organic phases were washed with water and brine. The organic layer was dried and filtered through celite and concentrated in vacuo.
  • (+/-)-ir «s-methyl 3-(((benzyloxy)carbonyl)amino)bicyclo[2.2.2]oct-5-ene- 2-carboxylate (16a)
  • (+/-)-ir «s-methyl 3-((2-bromo-5-fluoropyridin-4-yl)amino)bicyclo- [2.2.2] octane-2-carboxylate (18a)
  • Racemic- trans-methyl 3-aminobicyclo[2.2.2]octane-2-carboxylate (2.34 g, 12.75 mmol) in 1,4-dioxane (46 mL) was degassed under a stream of nitrogen for 15 minutes and this solution was added to the mixture of solids which was then evacuated and flushed with nitrogen three times again.
  • the reaction mixture was heated to 115 °C for 15 minutes.
  • the mixture was cooled to room temperature and flushed through a pad of celite.
  • the filtrate was concentrated in vacuo and the crude residue was purified by silica gel chromatography (EtOAc/Hexanes gradient) to afford the desired product.
  • (+/-)-ir «s-methyl 3-((2-(2-chloro-5-trityl-5H-pyrrolo[2,3-b]pyrazin-7-yl)- 5-fluoropyridin-4-yl)amino)bicyclo[2.2.2]octane-2-carboxylate (19a)
  • (+/-)-ir «s-methyl 3-((2-(2-chloro-5H-pyrrolo[2,3-b]pyrazin-7-yl)-5- fluoropyridin-4-yl)amino)bicyclo[2.2.2]octane-2-carboxylate (Comp. 1)
  • (+/-)-ir «s-3-((2-(2-chloro-5H-pyrrolo[2,3-b]pyrazin-7-yl)-5-fluoropyridin-
  • Lithium aluminum hydride (2.1 g, 59.4 mmol) was suspended in ether (150 mL) and cooled to 0 °C.
  • the mixture was stirred 2 hours in an ice bath then quenched slowly with IN HC1. The layers were separated and the aqueous layer was washed with ether.
  • N-benzylhydroxylamine (hydrochloric acid) (0.28 g, 1.80 mmol) and triethylamine (0.28 mL, 2.00 mmol) were added to a solution of methyl 3-(l-methylcyclobutyl)acrylate, 25a, (0.26 g, 1.50 mmol) in dichloromethane (9.5 mL).
  • the reaction mixture was stirred at 50 °C overnight.
  • the reaction mixture was cooled to room temperature and the mixture was diluted with dichloromethane and water. The layers were separated with a phase separator and the aqueous layer was washed with dichloromethane. The organic layers were combined and the volatiles removed under reduced pressure.
  • Racemic 3-amino-3-(l-methylcyclobutyl)propanoic acid, 27a, (2.3 g, 14.4 mmol) was dissolved in methanol (104 mL). The solution was cooled in an ice bath and acetyl chloride (5.6 g, 71.9 mmol) was added dropwise (Temp kept ⁇ 10 °C). The reaction mixture was heated to 65 °C and stirred at that temperature for 3 hours. The reaction mixture was cooled to room temperature and then flushed with toluene to remove volatiles. Crude racemic 3- methoxy-l-(l-methylcyclobutyl)-3-oxopropan-l-aminium chloride, 28a, was used without further purification.
  • (IS, 3R)-3-(ethoxycarbonyl)cyclohexanecarboxylic acid starting material can be prepared following the literature procedures described in : Barnett, C. J., Gu, R. L., Kobierski, M. E., WO-2002024705, Stereoselective process for preparing cyclohexyl amine derivatives.
  • the aqueous layer was extracted with EtOAc (2x75 mL) and the combined organic extracts were washed with water (lOOmL) and brine (100 mL), dried over Na 2 S0 4 and concentrated in vacuo.
  • the crude material was purified by silica gel chromatography (0%-50% EtOAc/hexanes) to provide the product (15.3 g, containing -25% benzyl alcohol), which was used for the next step without further purification.
  • thiophene-3-carbonyl chloride (0.009 g, 0.062 mmol) was added. Monitoring of the reaction by LC-MS showed both mono and bis-acylation products. The mixture was quenched with 2 ⁇ NaOH and stirred for 5 min to cleave any of the indole- thiophene amide side-product. The mixture was diluted with EtOAc and neutralized with 2N HC1, separated and extracted three times with EtOAc. The combined organic phases were dried (Na 2 S0 4 ), filtered and concentrated in vacuo.
  • CPE cytopathic effect
  • a second cell-based antiviral assay was developed that depends on the multiplication of virus-specific RNA molecules in the infected cells, with RNA levels being directly measured using the branched-chain DNA (bDNA), hybridization method (Wagaman et al, J. Virol Meth, 105: 105-114, 2002).
  • bDNA branched-chain DNA
  • cells are initially infected in wells of a 96- well microtiter plate, the virus is allowed to replicate in the infected cells and spread to additional rounds of cells, then the cells are lysed and viral RNA content is measured. This assay is stopped earlier that the CPE assay, usually after 18-36 hours, while all the target cells are still viable.
  • Viral RNA is quantitated by hybridization of well lysates to specific oligonucleotide probes fixed to wells of an assay plate, then amplification of the signal by hybridization with additional probes linked to a reporter enzyme, according to the kit manufacturer's instructions (Quantigene 1.0, Panomics, Inc.). Minus-strand viral RNA is measured using probes designed for the consensus type A hemagglutination gene. Control wells containing cells and virus were used to define the 100% viral replication level, and dose-response curves for antiviral test compounds were analyzed using 4-parameter curve fitting methods. The concentration of test compound resulting in viral RNA levels equal to that of 50% of the control wells were reported as EC5 0 .
  • DMEM Dulbecco's Modified Eagle Medium
  • 2mM L-glutamine 2mM L-glutamine
  • l,000U/ml penicillin
  • 1,000 ug/ml streptomycin 10 mM HEPES
  • 10% fetal bovine medium 10% fetal bovine medium.
  • CPE assay the day before the assay, cells were suspended by trypsinization and 10,000cells per well were distributed to wells of a 384 well plate in 50 ⁇ . On the day of the assay, adherent cells were washed with three changes of DMEM containing lug/ml TPCK-treated trypsin, without fetal bovine serum.
  • Assays were initiated with the addition of 30 TCID 50 of virus and test compound, in medium containing 1 ⁇ g/ml TPCK-treated trypsin, in a final volume of 50 ⁇ . Plates were incubated for 72 hours at 37°C in a humidified, 5% CO 2 atmosphere.
  • cells were grown in DMEM + fetal bovine serum as above, but on the day of the assay they were trypsinized, washed 2 times and suspended in serum-free EX-Cell MDCK cell medium (SAFC Biosciences, Lenexa, KS) and plated into wells at 20,000 cells per well. These wells were then used for assay after 5 hours of incubation, without the need for washing.
  • serum-free EX-Cell MDCK cell medium SAFC Biosciences, Lenexa, KS
  • Influenza virus strain A/PR/8/34 (tissue culture adapted) was obtained from ATCC
  • ICso and EC5 0 values of Compound 6 were 0.01 ⁇ and 0.009 ⁇ .
  • Table 1 IC50, EC50, NMR and LCMS Data of Compounds of Invention.

Abstract

La présente invention concerne un composé selon la formule (I) : ou son sel pharmaceutiquement acceptable, les valeurs de la formule développée étant telles que décrites ici. Une composition pharmaceutique comprend une quantité efficace dudit composé ou de son sel pharmaceutiquement acceptable, et un vecteur, un adjuvant ou un véhicule pharmaceutiquement acceptable. L'invention concerne l'utilisation du composé dans l'inhibition de la réplication de virus de la grippe dans un échantillon biologique ou un patient, et dans la réduction de la quantité de virus de la grippe dans un échantillon biologique ou un patient.
PCT/US2013/044636 2012-06-08 2013-06-07 Inhibiteurs de la réplication de virus de la grippe WO2013184985A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13729577.0A EP2858984A1 (fr) 2012-06-08 2013-06-07 Inhibiteurs de la réplication de virus de la grippe

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657236P 2012-06-08 2012-06-08
US61/657,236 2012-06-08

Publications (1)

Publication Number Publication Date
WO2013184985A1 true WO2013184985A1 (fr) 2013-12-12

Family

ID=48628957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/044636 WO2013184985A1 (fr) 2012-06-08 2013-06-07 Inhibiteurs de la réplication de virus de la grippe

Country Status (2)

Country Link
EP (1) EP2858984A1 (fr)
WO (1) WO2013184985A1 (fr)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829007B2 (en) 2009-06-17 2014-09-09 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US9051319B2 (en) 2011-08-01 2015-06-09 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CN106478460A (zh) * 2016-09-28 2017-03-08 衢州学院 一种手性N‑Boc‑3‑氨基‑4‑芳基‑丁酸的合成方法
WO2017060470A1 (fr) * 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Dérivés de pyrrolopyrazine destinés à être utilisés dans le traitement, le soulagement ou la prévention de la grippe
WO2017118680A1 (fr) * 2016-01-07 2017-07-13 Janssen Sciences Ireland Uc Acides pentanoïques fonctionnalisés à utiliser dans des infections à virus influenza
WO2017125506A1 (fr) * 2016-01-20 2017-07-27 Janssen Sciences Ireland Uc Pyrimidines à substitution aryle à utiliser dans une infection par le virus de la grippe
WO2017133670A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de pyridine et de pyrimidine et leur utilisation dans le traitement, l'atténuation des symptômes ou la prévention de la grippe
WO2017133658A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de 4,7-diazaindole et 4,7-diazaindazole et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes
WO2017133664A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés bicycliques de pyridine et de pyrimidine et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes
WO2017133667A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de pyrimidine et de pyridine et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes
WO2017133657A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de pyridine et de pyrimidine et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes
WO2017133665A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de 6,7-diazaindazole et de 6,7-diazaindole et leur utilisation dans le traitement, l'atténuation des symptômes ou la prévention de la grippe
JP2017523225A (ja) * 2014-08-08 2017-08-17 ヤンセン・サイエンシズ・アイルランド・ユーシー インフルエンザウイルス感染に使用するためのインドール類
US9771361B2 (en) 2013-11-13 2017-09-26 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2018108125A1 (fr) * 2016-12-15 2018-06-21 Sunshine Lake Pharma Co., Ltd. Inhibiteurs de réplication du virus de la grippe et utilisations associées
US10023569B2 (en) 2013-11-13 2018-07-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
CN108727369A (zh) * 2017-04-25 2018-11-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
US10273233B2 (en) 2015-05-13 2019-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US10501444B2 (en) 2016-08-16 2019-12-10 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
US10533004B2 (en) 2015-05-13 2020-01-14 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US10626108B2 (en) 2015-11-27 2020-04-21 Janssen Sciences Ireland Uc Heterocyclic indoles for use in influenza virus infection
US10647693B2 (en) 2016-08-30 2020-05-12 North & South Brother Pharmacy Investment Company Limited Inhibitors of influenza virus replication, application methods and uses thereof
US10717732B2 (en) 2015-12-09 2020-07-21 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
US10927118B2 (en) 2017-03-02 2021-02-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
US11098042B2 (en) 2017-01-05 2021-08-24 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015798A1 (fr) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Nouvelle methode virocide/inhibitrice de la proliferation virale et nouvel analogue de pyradine nucleotide/pyradine nucleoside
WO2005095400A1 (fr) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles utiles comme inhibiteurs de janus kinases et d'autres proteines kinases
WO2006058074A1 (fr) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines et pyrazolopyrazines convenant inhibiteurs de proteines-kinases
WO2007084557A2 (fr) 2006-01-17 2007-07-26 Vertex Pharmaceuticals Incorporated Azaindoles utiles comme inhibiteurs de janus kinases
WO2009073300A1 (fr) 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated Dérivés de [1h-pyrazolo[3,4-b]pyridin-4-yl]-phényle ou -pyridin-2-yle en tant qu'inhibiteurs de la protéine kinase c-thêta
WO2010011768A1 (fr) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Inhibiteurs de pyrazolopyridine kinase tricylique
WO2010011772A2 (fr) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Inhibiteurs de la pyrazolopyridine kinase tricyclique
WO2010011756A1 (fr) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Inhibiteurs de la pyrazolopyridine kinase
WO2010148197A1 (fr) * 2009-06-17 2010-12-23 Vertex Pharmaceuticals Incorporated Inhibiteurs de la réplication des virus de la grippe

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015798A1 (fr) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Nouvelle methode virocide/inhibitrice de la proliferation virale et nouvel analogue de pyradine nucleotide/pyradine nucleoside
WO2005095400A1 (fr) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles utiles comme inhibiteurs de janus kinases et d'autres proteines kinases
WO2006058074A1 (fr) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines et pyrazolopyrazines convenant inhibiteurs de proteines-kinases
WO2007084557A2 (fr) 2006-01-17 2007-07-26 Vertex Pharmaceuticals Incorporated Azaindoles utiles comme inhibiteurs de janus kinases
WO2009073300A1 (fr) 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated Dérivés de [1h-pyrazolo[3,4-b]pyridin-4-yl]-phényle ou -pyridin-2-yle en tant qu'inhibiteurs de la protéine kinase c-thêta
WO2010011768A1 (fr) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Inhibiteurs de pyrazolopyridine kinase tricylique
WO2010011772A2 (fr) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Inhibiteurs de la pyrazolopyridine kinase tricyclique
WO2010011756A1 (fr) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Inhibiteurs de la pyrazolopyridine kinase
WO2010148197A1 (fr) * 2009-06-17 2010-12-23 Vertex Pharmaceuticals Incorporated Inhibiteurs de la réplication des virus de la grippe

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
"Handbook of Chemistry and Physics"
CHOU, T.C.; TALALAY, P., ADV. ENZYME REGUL., vol. 22, 1984, pages 27 - 55
DE CLERCQ ERIK: "Antiviral agents active against influenza A viruses", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 5, no. 12, 1 December 2006 (2006-12-01), pages 1015 - 1025, XP002488967, ISSN: 1474-1784, DOI: 10.1038/NRD2175 *
E. W. MARTIN: "Remington's Pharmaceutical Sciences, Sixteenth Edition,", 1980, MACK PUBLISHING CO.
GREENE, T. W.; WUTS, P. G: "Protective Groups in Organic Synthesis, Third Edition,", 1999, JOHN WILEY & SONS
GREENE, T.W.; WUTS, P. G: "Protective Groups in Organic Synthesis, Third Edition,", 1999, JOHN WILEY & SONS
HOLFORD, N.H.G.; SCHEINER, L.B., CLIN. PHARMACOKINET., vol. 6, 1981, pages 429 - 453
JANET S. DODD,: "The ACS Style Guide: A Manual for Authors and Editors, 2nd Ed.,", 1997, AMERICAN CHEMICAL SOCIETY
LOEWE, S.; MUISCHNEK, H., ARCH. EXP. PATHOL PHARMACOL., vol. 114, 1926, pages 313 - 326
MANFRED E. WOLFF: "BURGER'S MEDICINAL CHEMISTRY AND DRUG DISCOVERY, 5th ed", 1995, pages: 172 - 178,949-
NOAH ET AL., ANTIVIRAL RES., vol. 73, 2006, pages 50 - 60
RURUTA ET AL.: "T-705 (flavipiravir) and related compounds: Novel broad- spectrum inhibitors of RNA viral infections.", ANTIVIRAL REASEARCH, vol. 82, 2009, pages 95 - 102, XP026018728, DOI: doi:10.1016/j.antiviral.2009.02.198
S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
SMITH, M.B. AND MARCH, J.,: "March's Advanced Organic Chemistry, 5th Ed.,", 2001, JOHN WILEY & SONS
THOMAS SORRELL: "Organic Chemistry", 1999, UNIVERSITY SCIENCE BOOKS
WAGAMAN ET AL., J. VIROL METH, vol. 105, 2002, pages 105 - 114

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10039762B2 (en) 2009-06-17 2018-08-07 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US9518056B2 (en) 2009-06-17 2016-12-13 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US8829007B2 (en) 2009-06-17 2014-09-09 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US10874673B2 (en) 2009-06-17 2020-12-29 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US9808459B2 (en) 2009-06-17 2017-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US9345708B2 (en) 2009-06-17 2016-05-24 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US9394302B2 (en) 2011-08-01 2016-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US9908878B2 (en) 2011-08-01 2018-03-06 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US10875855B2 (en) 2011-08-01 2020-12-29 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US9051319B2 (en) 2011-08-01 2015-06-09 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US11345700B2 (en) 2013-11-13 2022-05-31 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US10640501B2 (en) 2013-11-13 2020-05-05 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US9771361B2 (en) 2013-11-13 2017-09-26 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US10023569B2 (en) 2013-11-13 2018-07-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US10597390B2 (en) 2014-08-08 2020-03-24 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
JP2017523225A (ja) * 2014-08-08 2017-08-17 ヤンセン・サイエンシズ・アイルランド・ユーシー インフルエンザウイルス感染に使用するためのインドール類
US10273233B2 (en) 2015-05-13 2019-04-30 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
US10533004B2 (en) 2015-05-13 2020-01-14 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2017060470A1 (fr) * 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Dérivés de pyrrolopyrazine destinés à être utilisés dans le traitement, le soulagement ou la prévention de la grippe
US10626108B2 (en) 2015-11-27 2020-04-21 Janssen Sciences Ireland Uc Heterocyclic indoles for use in influenza virus infection
US10717732B2 (en) 2015-12-09 2020-07-21 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
US11225477B2 (en) 2015-12-09 2022-01-18 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
US10526338B2 (en) 2016-01-07 2020-01-07 Janssen Sciences Ireland Uc Functionalized pentanoic acids for use influenza viral infections
CN108473493B (zh) * 2016-01-07 2022-05-27 爱尔兰詹森科学公司 用于流感病毒感染的官能化的戊酸
CN108473493A (zh) * 2016-01-07 2018-08-31 爱尔兰詹森科学公司 用于流感病毒感染的官能化的戊酸
WO2017118680A1 (fr) * 2016-01-07 2017-07-13 Janssen Sciences Ireland Uc Acides pentanoïques fonctionnalisés à utiliser dans des infections à virus influenza
JP2019507119A (ja) * 2016-01-20 2019-03-14 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー インフルエンザウイルス感染における使用のためのアリール置換ピリミジン
US10611755B2 (en) 2016-01-20 2020-04-07 Janssen Sciences Ireland Uc Aryl substituted pyrimidines for use in influenza virus infection
CN108473477A (zh) * 2016-01-20 2018-08-31 爱尔兰詹森科学公司 用于在流感病毒感染中使用的芳基取代的嘧啶
WO2017125506A1 (fr) * 2016-01-20 2017-07-27 Janssen Sciences Ireland Uc Pyrimidines à substitution aryle à utiliser dans une infection par le virus de la grippe
CN108473477B (zh) * 2016-01-20 2021-10-22 爱尔兰詹森科学公司 用于在流感病毒感染中使用的芳基取代的嘧啶
US11117887B2 (en) 2016-01-20 2021-09-14 Janssen Sciences Ireland Unlimited Company Aryl substituted pyrimidines for use in influenza virus infection
WO2017133667A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de pyrimidine et de pyridine et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes
WO2017133665A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de 6,7-diazaindazole et de 6,7-diazaindole et leur utilisation dans le traitement, l'atténuation des symptômes ou la prévention de la grippe
WO2017133657A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de pyridine et de pyrimidine et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes
WO2017133670A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de pyridine et de pyrimidine et leur utilisation dans le traitement, l'atténuation des symptômes ou la prévention de la grippe
WO2017133664A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés bicycliques de pyridine et de pyrimidine et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes
WO2017133658A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de 4,7-diazaindole et 4,7-diazaindazole et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes
US10501444B2 (en) 2016-08-16 2019-12-10 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
US10647693B2 (en) 2016-08-30 2020-05-12 North & South Brother Pharmacy Investment Company Limited Inhibitors of influenza virus replication, application methods and uses thereof
CN106478460B (zh) * 2016-09-28 2018-06-12 衢州学院 一种手性N-Boc-3-氨基-4-芳基-丁酸的合成方法
CN106478460A (zh) * 2016-09-28 2017-03-08 衢州学院 一种手性N‑Boc‑3‑氨基‑4‑芳基‑丁酸的合成方法
US10987354B2 (en) * 2016-12-15 2021-04-27 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN108218873A (zh) * 2016-12-15 2018-06-29 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
JP2020513415A (ja) * 2016-12-15 2020-05-14 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド インフルエンザウイルス複製の阻害剤及びその使用
JP7034162B2 (ja) 2016-12-15 2022-03-11 サンシャイン・レイク・ファーマ・カンパニー・リミテッド インフルエンザウイルス複製の阻害剤及びその使用
KR20190092545A (ko) * 2016-12-15 2019-08-07 선샤인 레이크 파르마 컴퍼니 리미티드 인플루엔자 바이러스 복제의 억제제 및 이의 용도
WO2018108125A1 (fr) * 2016-12-15 2018-06-21 Sunshine Lake Pharma Co., Ltd. Inhibiteurs de réplication du virus de la grippe et utilisations associées
KR102554019B1 (ko) 2016-12-15 2023-07-11 선샤인 레이크 파르마 컴퍼니 리미티드 인플루엔자 바이러스 복제의 억제제 및 이의 용도
US11098042B2 (en) 2017-01-05 2021-08-24 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
US10927118B2 (en) 2017-03-02 2021-02-23 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN108727369A (zh) * 2017-04-25 2018-11-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN108727369B (zh) * 2017-04-25 2023-06-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途

Also Published As

Publication number Publication date
EP2858984A1 (fr) 2015-04-15

Similar Documents

Publication Publication Date Title
US10875855B2 (en) Inhibitors of influenza viruses replication
US8871774B2 (en) Inhibitors of influenza viruses replication
WO2013184985A1 (fr) Inhibiteurs de la réplication de virus de la grippe
WO2012083121A1 (fr) Inhibiteurs de réplication de virus de la grippe
US20130345218A1 (en) Inhibitors of influenza viruses replication
OA19823A (en) Inhibitors of influenza viruses replication.
NZ620086B2 (en) Inhibitors of influenza viruses replication
NZ716783B2 (en) Inhibitors of influenza viruses replication
OA17028A (en) Inhibitors of influenza viruses replication.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13729577

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE